<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11040716</article-id>
    <article-id pub-id-type="pmid">38563534</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.3c01979</article-id>
    <article-categories>
      <subj-group>
        <subject>Application Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MolProphet: A One-Stop,
General Purpose, and AI-Based
Platform for the Early Stages of Drug Discovery</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-9368-9737</contrib-id>
        <name>
          <surname>Yang</surname>
          <given-names>Keda</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Xie</surname>
          <given-names>Zewen</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Li</surname>
          <given-names>Zhen</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <name>
          <surname>Qian</surname>
          <given-names>Xiaoliang</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Sun</surname>
          <given-names>Nannan</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath6">
        <name>
          <surname>He</surname>
          <given-names>Tao</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath7">
        <name>
          <surname>Xu</surname>
          <given-names>Zuodong</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath8">
        <name>
          <surname>Jiang</surname>
          <given-names>Jing</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath9">
        <name>
          <surname>Mei</surname>
          <given-names>Qi</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath10">
        <name>
          <surname>Wang</surname>
          <given-names>Jie</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath11">
        <name>
          <surname>Qu</surname>
          <given-names>Shugang</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath12">
        <name>
          <surname>Xu</surname>
          <given-names>Xiaoling</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath13">
        <name>
          <surname>Chen</surname>
          <given-names>Chaoxiang</given-names>
        </name>
        <xref rid="cor2" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath14">
        <name>
          <surname>Ju</surname>
          <given-names>Bin</given-names>
        </name>
        <xref rid="cor3" ref-type="other">*</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Key
Laboratory of Artificial Organs and Computational Medicine in Zhejiang
Province, Shulan International Medical College, <institution>Zhejiang Shuren University</institution>, Hangzhou 310015, <country>P. R. China</country></aff>
      <aff id="aff2"><label>‡</label><institution>Hangzhou
SanOmics Information Technology Co., Ltd.</institution>, Hangzhou 310015, <country>P. R. China</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label><email>ziyao1988@zju.edu.cn</email>.</corresp>
      <corresp id="cor2"><label>*</label><email>ccx@zjsru.edu.cn</email>.</corresp>
      <corresp id="cor3"><label>*</label><email>jubin_hz@163.com</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>02</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>22</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <volume>64</volume>
    <issue>8</issue>
    <fpage>2941</fpage>
    <lpage>2947</lpage>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>21</day>
        <month>03</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>20</day>
        <month>03</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0004" id="ab-tgr1"/>
      </p>
      <p>Artificial intelligence
(AI) is an effective tool to
accelerate
drug discovery and cut costs in discovery processes. Many successful
AI applications are reported in the early stages of small molecule
drug discovery. However, most of those applications require a deep
understanding of software and hardware, and focus on a single field
that implies data normalization and transfer between those applications
is still a challenge for normal users. It usually limits the application
of AI in drug discovery. Here, based on a series of robust models,
we formed a one-stop, general purpose, and AI-based drug discovery
platform, MolProphet, to provide complete functionalities in the early
stages of small molecule drug discovery, including AI-based target
pocket prediction, hit discovery and lead optimization, and compound
targeting, as well as abundant analyzing tools to check the results.
MolProphet is an accessible and user-friendly web-based platform that
is fully designed according to the practices in the drug discovery
industry. The molecule screened, generated, or optimized by the MolProphet
is purchasable and synthesizable at low cost but with good drug-likeness.
More than 400 users from industry and academia have used MolProphet
in their work. We hope this platform can provide a powerful solution
to assist each normal researcher in drug design and related research
areas. It is available for everyone at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Ministry of Science and Technology of the People''s Republic of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100002855</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>G2022016010L</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Scientific Research Fund of Zhejiang Provincial Education Department</institution>
            <institution-id institution-id-type="doi">NA</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>Y202352312</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Zhejiang Health Information Association Research Program</institution>
            <institution-id institution-id-type="doi">NA</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2023XHSZ-Z05</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Fundamental Research Funds for the Central Universities</institution>
            <institution-id institution-id-type="doi">10.13039/501100012226</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022ZFJH003</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Zhejiang Province</institution>
            <institution-id institution-id-type="doi">10.13039/501100004731</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>LD22H300004</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci3c01979</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci3c01979</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>AI
(artificial intelligence)
has the potential to significantly
accelerate the process of bringing new drugs to market, while also
reducing the costs and risks involved in drug development.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> A lot of AI tools, such as DeepChem,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Deep Docking,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> DeepPocket,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and AlphaFold,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> have
been developed and increasingly used in the discovery process, especially
in the discovery of small molecule drugs. However, most of those applications
still require a deep understanding of software and hardware and focus
on a single field that implies data normalization and transfer between
those applications, which are still challenges for normal researchers.
On the other side, the high cost of the hardware and software of AI/computational
chemistry is sometimes a barrier to many researchers and startups
to manipulate the power of AI to accelerate their drug discovery projects.</p>
    <p>The success of virtual screening (VS) in drug discovery depends
on the availability and quality of the compound library as well as
the accuracy and validation of the computational methods used. Hence,
building and curating a diverse and representative compound library
are crucial for identifying lead compounds with potential pharmacological
activities. A compound database is indispensable in performing AI-based
VS. Many databases were created to provide the SMILES of compounds,
for example, PubChem,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> ChEMBL,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> ChemSpider,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Zinc,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Drugbank,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and so
on, to perform structure-based virtual screening (SBVS) and ligand-based
virtual screening (LBVS). But, voluminous data are difficult to process,
and there is a need for specialized skills and computational resources
for data retrieval and utilization. Additionally, differences in data
naming and formatting across databases may require extra data processing
and formatting.</p>
    <p>The chemical space may contain 1 × 10<sup>60</sup> molecules.
It would be more productive if candidate molecules are generated,
rather than screened from libraries, with suitable absorption, distribution,
metabolism, excretion, and toxicity (ADMET) properties as prerequisites
at the beginning of the molecule design process.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> AI molecule generation models are widely used for designing
drug candidates using prior biological and chemical knowledge in drug
discovery.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> By using a combination of AI
generative techniques and reinforcement learning, Insilico Medicine
successfully created new discoidin domain receptor 1 (DDR1) kinase
inhibitors to treat fibrosis in only 21 days.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Despite all generated molecules being chemically meaningful, they
may be too difficult/expensive to synthesize and have poor drug-like
properties. In practice, only very few results generated by AI are
synthesized and tested in a wet experiment, due to the potential value
of this molecule being smaller than the cost to synthesize that molecule.</p>
    <p>To remove the barriers in using AI technology, integrating multicompound
databases and generating molecules with good drug-like properties
and synthetic accessibility for normal researchers, we developed the
SaaS (Software as a Service) and cocreation platform MolProphet (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>). It aims to make AI technology more accessible to each investigator
who works in new drug discovery. The generated molecule in the results
is easy to synthesize, and the drug-likeness of each molecular is
accessed as well. MolProphet provides a one-stop, general purpose
online drug discovery platform to help investigators accelerate their
new drug development process. The platform mainly focuses on the early
stages of drug discovery, especially on hits discovery and the hits-to-leads
stage. In the following sections, we describe the key features of
the MolProphet platform.</p>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Implementation</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Framework of MolProphet</title>
      <p>The framework
of MolProphet is shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. This framework consists of a series of interconnected
modules and tools that collect protein and compound data, generate
molecules, and facilitate the analysis of biological data, prediction
of compound properties, and optimization of drug-like molecules. Initially,
the pocket discovery and management module enable the identification
and management of protein pockets. These pockets, once identified,
can be easily utilized by other key modules. Alternatively, if the
3D structure of the protein is not available, the framework allows
for starting from a reference molecule. Then, the framework provides
key modules such as structure-based or ligand-based screening, AI
molecule generation, AI docking, and optimization. These modules aid
in the discovery of potential small molecular structures. In the subsequent
steps, analysis tools are available to provide crucial data including
3D structure, binding mode, drug-likeness, synthetic pathway, and
more. This data assists researchers in selecting potential molecules
for further investigation. Moreover, the selected or starred molecules
can undergo verification through wet experiments. Finally, the molecules
identified through experiment can be further optimized within the
software framework, forming a closed loop. At the same time, experimental
data can be used to fine-tune the software models, enhancing the predictive,
screening, and generating capabilities in subsequent iterations.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Framework
of the AI-based drug discovery platform MolProphet.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0001" id="gr1" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec2.2">
    <label>3</label>
    <title>Key Modules</title>
    <p>The theoretical background
and methods of key modules are briefly
introduced in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>. The functions of these key modules are outlined below.</p>
    <sec id="sec2.2.1">
      <label>3.1</label>
      <title>Pocket Discovery and Management Module</title>
      <p>In the process
of new drug development, finding the correct target
pocket structure can greatly improve the development efficiency. This
module is designed to help users quickly define pocket structures
as the basis for subsequent molecular screening, design, optimization,
and evaluation. The platform uses deep learning algorithms to automatically
predict one to five most competitive pocket structures for each protein
and form a 3D visual selection interface. Besides automated pocket
prediction, the pockets can be established by defining a set of key
amino acid residues manually at first. Then, a set of self-developed
intelligent algorithms automatically completes the pocket structures.
Furthermore, the module creates an associated profile for each pocket
that can be viewed and recalled at any time. In addition, more functions,
such as defining the pocket structure precisely to each amino acid
site, etc., will be added to the module in the future to suit the
needs of different application scenarios. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> shows a sample output of pocket identification.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Output
of pocket prediction and definition module (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="6X1A">6X1A</ext-link>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0002" id="gr2" position="float"/>
      </fig>
      <p>Data from wet lab experiments on target pockets
can be uploaded
and utilized to fine-tune the pretrained activity prediction model.
The refined activity prediction model will then be employed for molecular
ranking in subsequent screening, generation, and optimization tasks.</p>
    </sec>
    <sec id="sec2.2.2">
      <label>3.2</label>
      <title>Structure-Based Drug Discovery Module</title>
      <p>In
order to reduce the synthesis costs in the early stages of drug
discovery, commercial purchasable compound libraries are usually screened
in the industry. But the traditional CADD virtual screening method
has been suffering from slow screening efficiency. Therefore, this
module aims to quickly complete the virtual screening of commercially
purchasable compound libraries by AI technology. The core of this
module is a deep neural network, trained by using 18 million real
bioassay data to predict the affinity between targets and ligands.
It surpasses traditional techniques in terms of universal positive
rates and enrichment factors. Moreover, it has accomplished the screening
of a billion orders of magnitude molecules within a week. The screening
of tens of millions of molecules can be completed very quickly on
the online platform.</p>
    </sec>
    <sec id="sec2.2.3">
      <label>3.3</label>
      <title>Ligand-Based Drug Discovery
Module</title>
      <p>This module aims to quickly retrieve molecules similar
to known molecules
in commercial libraries through AI algorithms. It includes a 2D structure
similarity algorithm (the output result has high similarity in the
molecular structure), which enables the retrieval of millions of molecular
data in 1 min by using a 2D structure based on graphical neural network
representation and the vector search Milvus algorithm. The 3D pharmacophore
similarity algorithm (the output result has high structural variation)
is included as well, and it can code 3D features for 1 billion molecules
in 1 day.</p>
    </sec>
    <sec id="sec2.2.4">
      <label>3.4</label>
      <title>AI Molecular Generative
Module</title>
      <p>This
module aims to generate novel, low-cost, and easily synthesized molecules
using AI technology. Unlike many AI molecule generation algorithms
that primarily focus on activity without considering drug-like properties
and synthesizability, this module prioritizes drug-likeness, ease
of synthesis, and cost-effectiveness as core indicators. It directly
generates molecules from procurable building blocks and provides a
synthesis solution for each generated molecule. The synthesis solution
includes the top 300 most frequently used reaction templates from
over 1000 known reaction templates,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> based
on more than 3 million explicit examples and expert-selected templates.
Additionally, over 500,000 procurable building blocks<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> are prepared to match these templates, enabling efficient
and accessible synthesis of the desired molecules. In practice, 70%
of AI generated molecules can be synthesized within 3–4 steps
under simple reaction conditions by cheap building blocks. A sample
case of a synthetic pathway and template is shown in Figures S13 and
S14 of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>, respectively.</p>
    </sec>
    <sec id="sec2.2.5">
      <label>3.5</label>
      <title>Molecule Optimization Modules</title>
      <p>Molecular
optimization modules are powerful tools that enable users to optimize
molecules using a variety of methods. One of the key features of the
module is its ability to optimize molecules by scaffold hopping, fragment,
and R-group. This means that users can select the optimization method
that best suits their needs, whether they want to optimize the entire
molecule or only specific portions of it.</p>
      <p>By using the scaffold
hopping optimization method, the molecular optimization module will
optimize the entire structure of the molecule, making it more stable
and potentially more effective. This method is particularly useful
for users who work with small molecules or compounds with simple structures.</p>
      <p>Alternatively, users can choose to optimize their molecules by
fragment. This method focuses on optimizing the core structure of
the molecule while leaving the peripheral groups intact. This is particularly
useful for users who are working with molecules that have complex
peripheral structures but a simple core.</p>
      <p>Finally, the R-group
optimization method is designed for users
who want to optimize specific R groups of their molecules. This method
enables users to optimize individual R-groups within a molecule while
leaving the rest of the structure intact. This is particularly useful
for users who work with complex molecules with multiple functional
R-groups.</p>
    </sec>
    <sec id="sec2.2.6">
      <label>3.6</label>
      <title>AI Docking Module</title>
      <p>This module aims
to help practitioners perform rapid evaluation of a molecular data
set (usually ligand-based screening results or user-owned molecular
data set) through AI technology. Based on geometric deep learning,
it learns target pocket information and small molecule structure information;
reinforcement learning is used to sample the receptor flexible conformation
while optimizing the binding conformation of the ligand molecule to
predict the minimum free energy of molecule binding to the target
pocket.</p>
    </sec>
  </sec>
  <sec id="sec2.3">
    <label>4</label>
    <title>Integrated Compound Database</title>
    <p>Compound
databases are important for structural-based or ligand-based
virtual screening. The platform not only includes multipublic compound
databases but also includes compound data developed by ourselves. <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref> shows the details
of compound databases from public sources (CDPSs). <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> shows MolProphet ’s
target focused compound library (TFCL). There are about 3.98 billion
molecules in CDPSs. It should be noted that all compounds in CDPSs
are purchasable from the Web site of vendors. TFCL is selected from
CDPSs or generated by an AI model focused on the properties of compounds
with diversity, novelty, and accessibility. The TFCL was divided into
15 sublibraries with about total 1 M molecules. The molecules generated
by AI can be synthesized easily from building blocks. It should be
noted that only isomeric SMILES are stored in the TFCL and CDPSs.
The conformers are not stored in the database and generated by RDkit
from SMILES.</p>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <title>Compound Databases Integrated in the
Platform from Public Sources</title>
      </caption>
      <table frame="hsides" rules="groups" border="0">
        <colgroup>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead>
          <tr>
            <th style="border:none;" align="center">
              <bold>Public
Compound Databases</bold>
            </th>
            <th style="border:none;" align="center">
              <bold>Size</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td style="border:none;" align="left">TopScience</td>
            <td style="border:none;" align="left">7,272,880</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChEMBL<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></td>
            <td style="border:none;" align="left">2,136,186</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChEMBL Clinical<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></td>
            <td style="border:none;" align="left">5,014</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChemBridge<sup><xref ref-type="bibr" rid="ref18">18</xref></sup></td>
            <td style="border:none;" align="left">1,543,545</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Chemdiv<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></td>
            <td style="border:none;" align="left">1,601,800</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Chemspace<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></td>
            <td style="border:none;" align="left">6,078,492</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">DrugBank<sup><xref ref-type="bibr" rid="ref10">10</xref></sup></td>
            <td style="border:none;" align="left">2,709</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Selected from Enamine<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></td>
            <td style="border:none;" align="left">2,849,580</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Covalent Screening
Library<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></td>
            <td style="border:none;" align="left">11,199</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">InterBioScreen<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></td>
            <td style="border:none;" align="left">555,295</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ZINC<sup><xref ref-type="bibr" rid="ref24">24</xref></sup></td>
            <td style="border:none;" align="left">10,725,144</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Real
Space<sup><xref ref-type="bibr" rid="ref15">15</xref></sup></td>
            <td style="border:none;" align="left">3,900,000,000</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Diverse Structure
Molecules<sup><xref ref-type="bibr" rid="ref15">15</xref></sup></td>
            <td style="border:none;" align="left">48,232,770</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">
              <bold>Total</bold>
            </td>
            <td style="border:none;" align="left">
              <bold>3,981,014,614</bold>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="tbl2" position="float">
      <label>Table 2</label>
      <caption>
        <title>Target Focused Compound
Library from
MolProphet</title>
      </caption>
      <table frame="hsides" rules="groups" border="0">
        <colgroup>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead>
          <tr>
            <th style="border:none;" align="center">
              <bold>MolProphet’s
Target Focused Compound Library</bold>
            </th>
            <th style="border:none;" align="center">
              <bold>Size</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td style="border:none;" align="left">Clinical
and marketed libraries</td>
            <td style="border:none;" align="left">15030</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Natural product libraries</td>
            <td style="border:none;" align="left">35058</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Signaling pathway related
libraries</td>
            <td style="border:none;" align="left">188000</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Macrocyclic compound
library</td>
            <td style="border:none;" align="left">355455</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Anti-infection
and antivirus
libraries</td>
            <td style="border:none;" align="left">39153</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Highly selective
inhibitor
libraries</td>
            <td style="border:none;" align="left">40943</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Cell death related
libraries</td>
            <td style="border:none;" align="left">50870</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Antitumor compound
library</td>
            <td style="border:none;" align="left">53775</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Immune/Inflammatory
molecule
compound library</td>
            <td style="border:none;" align="left">40985</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Anticardiovascular
disease
compound library</td>
            <td style="border:none;" align="left">10846</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Antiaging compound
library</td>
            <td style="border:none;" align="left">30051</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Phenotypic screening
library</td>
            <td style="border:none;" align="left">52242</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Protease inhibitor
library</td>
            <td style="border:none;" align="left">6468</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Covalent inhibitor
library</td>
            <td style="border:none;" align="left">10846</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Metabolic related
libraries</td>
            <td style="border:none;" align="left">38392</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">
              <bold>Total</bold>
            </td>
            <td style="border:none;" align="left">
              <bold>968114</bold>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </sec>
  <sec id="sec2.4">
    <label>5</label>
    <title>Analysis Tools</title>
    <sec id="sec2.4.1">
      <label>5.1</label>
      <title>Oral Bioavailability Assessment
and Structural
Alerts</title>
      <p>During small molecule drug design, the Lipinski’s
rule of 5<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> is often used to evaluate oral
bioavailability of a compound. As shown in Figure S8 of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>, the platform evaluates
the compound by physicochemical properties such as molecular weight,
topological polar surface area, lipophilicity, and hydrogen bond donors/acceptors.</p>
      <p>In addition to the rule of 5 evaluation, it is important to identify
and address structural alerts in the proposed drug molecule. Structural
alerts are functional groups or substructures that have been associated
with toxicity or poor bioavailability in previous drug development
studies. By identifying and removing structural alerts in the design
phase, drug discovery teams can increase the chances of success in
clinical trials and decrease the risk of late-stage attritions due
to safety or efficacy concerns. Here, we provide BMS Rule,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Chelator Rule,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> PAINS
Rule,<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Genotoxic Carcinogenicity Rule,<sup><xref ref-type="bibr" rid="ref29">29</xref>−<xref ref-type="bibr" rid="ref32">32</xref></sup> NTD Rule,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> and SureChEMBL Rule<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> structural alerts.</p>
    </sec>
    <sec id="sec2.4.2">
      <label>5.2</label>
      <title>ADMET
Prediction</title>
      <p>ADMET prediction
is a crucial aspect of drug discovery and development. ADMET prediction
plays a vital role in predicting the safety and efficacy of a drug
before it is tested in clinical trials, which helps to reduce the
risk of drug failure and ensures patient safety. In the platform, <italic>Absorption</italic> is assessed by Caco2, Human Intestinal Absorption
(HIA), and P-glycoprotein (P-gp) Inhibitor. <italic>Bioavailability</italic> is assessed by Hydration Free Energy (HFE), Distribution, Blood-Brain
Barrier (BBB) Penetration, Plasma Protein Binding Ratio (PPBR), and
Volume of Distribution (VDSS). <italic>Metabolism</italic> is assessed
by CYP2D6 Inhibitor, CYP3A4 Inhibitor, CYP2C9 Inhibitor, CYP2D6 Substrate,
CYP3A4 Substrate, CYP2C9 Substrate, CYP2C19 Inhibitor, and CYP1A2
Inhibitor. Excretion is assessed by Half Life (hour) and Clearance
(mL/min/g). <italic>Toxicity</italic> is assessed by hERG, Drug-induced
Liver Injury (DILI), Aryl hydrocarbon Receptor (NR-AhR), Carcinogencity,
Median Lethal Dose (LD<sub>50</sub>), Respiratory toxicity, and Eye
Corrosion. The databases and methods used in ADMET prediction are
listed in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>.</p>
    </sec>
    <sec id="sec2.4.3">
      <label>5.3</label>
      <title>Binding Mode Assessment</title>
      <p>To rapidly
analyze the interaction characteristics between molecules and ligands,
the interactions present in different ways: (1) a 3D viewer of protein
and ligand (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a) [A 3D viewer of protein ligand allows researchers to visualize
and explore the spatial arrangement between a protein and a ligand
molecule. It provides valuable insights for drug design and optimization.];
(2) binding mode analysis (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b), i.e., the interactions between ligand and receptor
represented by different colors depend on the type of force; and (3)
binding site analysis (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>c), i.e., statistical analysis of binding sites for the possible
conformations of ligands. The vertical coordinate is the number of
ligand conformations predicted by AI, and the horizontal coordinate
is the amino acid site; different color statistics correspond to different
types of binding forces, and the statistics represent the number of
conformations where the current ligand has a binding force with that
amino acid site. More analysis tools such as toxic substructure hints,
generation of proprietary molecular reports, etc. will be added to
this module in the future.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>(a) 3D viewer of the protein and ligand, (b)
binding mode of the
ligand-protein, and (c) the analysis of interaction of the residue.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec2.5">
    <label>6</label>
    <title>Others</title>
    <sec id="sec2.5.1">
      <label>6.1</label>
      <title>User
Interface</title>
      <p>Recognizing that not
all users possess expertise in drug discovery software, the MolProphet
platform was carefully developed to ensure user-friendliness, minimizing
any potential hurdles. Each functional module within the system has
been streamlined to require just a few simple clicks, and every step
is accompanied by helpful hints to guide the users. This intuitive
design approach empowers ordinary users to swiftly navigate the platform
and effectively carry out projects, even without prior experience.</p>
      <p>Moreover, the MolProphet platform has preset multitype input data
methods for all modules (such as defining target pockets, submitting
reference molecules, etc.) to meet different usage scenarios. For
instance, when defining target pockets, users have the option to upload
local files for instant processing or search for standard PDB files
using PDB IDs sourced from the official PDB Web site (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</uri>). Similarly,
when setting reference molecules, users can choose from multiple options,
including direct molecular structure drawing, uploading local files,
inputting SMILES, or reading collection records. These flexible input
methods empower users to conveniently tailor their interactions with
the platform based on their specific needs.</p>
      <p>For result management,
the MolProphet platform provides task objectives
and conclusion record functions for each task, which provides convenience
for later review and also facilitates communication among users. Users
can also freely collect, download, and delete the results to meet
the needs of different scenarios. For each specific result molecule,
depending on the task, a corresponding result analysis interface is
provided, which can be viewed by clicking on the corresponding molecule
tab.</p>
      <p>In the future, the MolProphet platform will add more content
related
to results and records, including but not limited to automatically
generated task reports, molecular reports, experimental record management,
etc.</p>
    </sec>
    <sec id="sec2.5.2">
      <label>6.2</label>
      <title>Management System</title>
      <p>For project management,
the MolProphet platform establishes a set of project-based data management
solutions to solve users’ data management problems. Users can
create multiple projects with data isolated from each other. Each
project can invite different users to collaborate and share information
with the project. The platform also establishes an independent three-level
management system (PI, administrator, and general members) for each
project, which is convenient for users to manage their own research
teams.</p>
      <p>In terms of task management, users can check the progress
of tasks at any time while they are in progress, and they are also
allowed to cancel tasks that are in queue or in progress and to retry
at any time if there is an abnormality in the task (in some scenarios,
retrying can solve the abnormality). However, to avoid management
confusion, the platform restricts users from managing only the tasks
they have created.</p>
      <p>On the other hand, the platform separately
establishes a hybrid
cloud system for teams or companies with higher requirements of privacy
and confidentiality (e.g., pharmaceutical companies and research teams
with corresponding needs, etc.). It enables the instant distribution
of the latest models from the public cloud and ensures the security
of private cloud data.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>7</label>
    <title>Applications</title>
    <p>The
development of MolProphet
started in 2017, and since then,
the platform has been used in more than 20 hit discovery and lead
optimization projects with impressive results. The SaaS platform has
more than 400 users and has served in more than 600 projects until
today (December 10, 2023). The platform has been successful in identifying
compounds at the micromolar level, which have been further optimized
to achieve nanomolar levels. More details of application cases are
provided in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>.</p>
  </sec>
  <sec id="sec4">
    <label>8</label>
    <title>Conclusion</title>
    <p>MolProphet is a one-stop,
general purpose, and AI-based platform
for the early stages of small molecule drug discovery. It aims to
provide AI-based drug discovery tools to each normal researcher in
drug discovery. With MolProphet, users can access the platform from
anywhere, eliminating the need for a complex hardware or software
setup. Even without extensive knowledge in computational aid drug
discovery and AI, researchers in drug discovery can easily harness
the power of AIDD (AI-assisted drug discovery) to accelerate their
work.</p>
    <p>According to the practice in the industry, the platform
offers
a comprehensive suite of AI-based drug discovery tools for the early
stages of drug development. These include virtual screening, molecular
generation, and optimization functions. Our patented molecule generation
approach allows for direct generation of molecules from building blocks,
resulting in compounds with enhanced drug-likeness but easier and
cheaper to synthesize. The compound results from the virtual screening
are purchasable. In the optimization modules, the compounds can be
optimized by scaffold hopping, fragment, and R-group, which are valuable
for lead optimization.</p>
    <p>In summary, MolProphet is a valuable
online AIDD tool that empowers
researchers to accelerate their work in the early stages of small
molecule drug development.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes-2">
    <title>Data Availability Statement</title>
    <p>The software
is publicly available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>. Many modules, including virtual screening, are freely accessible
to all users. Trial software licenses can be provided to interested
readers. Data for training the models is constructed from publicly
available sources such as ChEMBL (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/">https://www.ebi.ac.uk/chembl/</uri>).</p>
  </notes>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting
Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.3c01979?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.3c01979</ext-link>.<list id="silist" list-type="simple"><list-item><p>1. Test application case
on MolProphet, 2. Software
technology framework of MolProphet, 3. Methods and the theoretical
background of modules, 4. Stability of AI molecule generation, 5.
Databases and methods used in ADMET prediction, 6. Fine-tune modules
with wet-lab experimental data, 7. The original images of <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_si_001.pdf">
        <caption>
          <p>ci3c01979_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e747-autogenerated">
    <p>The authors declare no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work is
supported by the Fundamental
Research Funds for
the Central Universities, grant No. 2022ZFJH003, the Ministry of Science
and Technology of the People’s Republic of China (No. G2022016010L),
the Scientific Research Fund of Zhejiang Provincial Education Department
(No. Y202352312), the Zhejiang Health Information Association Research
Program (No. 2023XHSZ-Z05), and the Natural Science Foundation of
Zhejiang Province (No. LD22H300004).</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Paul</surname><given-names>D.</given-names></name>; <name><surname>Sanap</surname><given-names>G.</given-names></name>; <name><surname>Shenoy</surname><given-names>S.</given-names></name>; <name><surname>Kalyane</surname><given-names>D.</given-names></name>; <name><surname>Kalia</surname><given-names>K.</given-names></name>; <name><surname>Tekade</surname><given-names>R. K.</given-names></name><article-title>Artificial intelligence
in drug discovery and development</article-title>. <source>DRUG DISCOV
TODAY</source><year>2021</year>, <volume>26</volume>, <fpage>80</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.10.010</pub-id>.<pub-id pub-id-type="pmid">33099022</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="book" id="cit2"><person-group person-group-type="allauthors"><name><surname>Ramsundar</surname><given-names>B.</given-names></name>; <name><surname>Eastman</surname><given-names>P.</given-names></name>; <name><surname>Walters</surname><given-names>P.</given-names></name>; <name><surname>Pande</surname><given-names>V.</given-names></name>; <name><surname>Leswing</surname><given-names>K.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name></person-group><source>Deep Learning for the Life Sciences</source>; <publisher-name>O’Reilly Media</publisher-name>: <year>2019</year>.</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Gentile</surname><given-names>F.</given-names></name>; <name><surname>Agrawal</surname><given-names>V.</given-names></name>; <name><surname>Hsing</surname><given-names>M.</given-names></name>; <name><surname>Ton</surname><given-names>A.</given-names></name>; <name><surname>Ban</surname><given-names>F.</given-names></name>; <name><surname>Norinder</surname><given-names>U.</given-names></name>; <name><surname>Gleave</surname><given-names>M. E.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name><article-title>Deep Docking:
A Deep Learning Platform for Augmentation of Structure Based Drug
Discovery</article-title>. <source>ACS CENTRAL SCI</source><year>2020</year>, <volume>6</volume>, <fpage>939</fpage>–<lpage>949</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.0c00229</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Aggarwal</surname><given-names>R.</given-names></name>; <name><surname>Gupta</surname><given-names>A.</given-names></name>; <name><surname>Chelur</surname><given-names>V.</given-names></name>; <name><surname>Jawahar</surname><given-names>C. V.</given-names></name>; <name><surname>Priyakumar</surname><given-names>U. D.</given-names></name><article-title>DeepPocket:
Ligand Binding Site Detection and Segmentation using 3D Convolutional
Neural Networks</article-title>. <source>J. CHEM INF MODEL</source><year>2022</year>, <volume>62</volume>, <fpage>5069</fpage>–<lpage>5079</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00799</pub-id>.<pub-id pub-id-type="pmid">34374539</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Jumper</surname><given-names>J.</given-names></name>; <name><surname>Evans</surname><given-names>R.</given-names></name>; <name><surname>Pritzel</surname><given-names>A.</given-names></name>; <name><surname>Green</surname><given-names>T.</given-names></name>; <name><surname>Figurnov</surname><given-names>M.</given-names></name>; <name><surname>Ronneberger</surname><given-names>O.</given-names></name>; <name><surname>Tunyasuvunakool</surname><given-names>K.</given-names></name>; <name><surname>Bates</surname><given-names>R.</given-names></name>; <name><surname>Žídek</surname><given-names>A.</given-names></name>; <name><surname>Potapenko</surname><given-names>A.</given-names></name>; <name><surname>Bridgland</surname><given-names>A.</given-names></name>; <name><surname>Meyer</surname><given-names>C.</given-names></name>; <name><surname>Kohl</surname><given-names>S. A. A.</given-names></name>; <name><surname>Ballard</surname><given-names>A. J.</given-names></name>; <name><surname>Cowie</surname><given-names>A.</given-names></name>; <name><surname>Romera-Paredes</surname><given-names>B.</given-names></name>; <name><surname>Nikolov</surname><given-names>S.</given-names></name>; <name><surname>Jain</surname><given-names>R.</given-names></name>; <name><surname>Adler</surname><given-names>J.</given-names></name>; <name><surname>Back</surname><given-names>T.</given-names></name>; <name><surname>Petersen</surname><given-names>S.</given-names></name>; <name><surname>Reiman</surname><given-names>D.</given-names></name>; <name><surname>Clancy</surname><given-names>E.</given-names></name>; <name><surname>Zielinski</surname><given-names>M.</given-names></name>; <name><surname>Steinegger</surname><given-names>M.</given-names></name>; <name><surname>Pacholska</surname><given-names>M.</given-names></name>; <name><surname>Berghammer</surname><given-names>T.</given-names></name>; <name><surname>Bodenstein</surname><given-names>S.</given-names></name>; <name><surname>Silver</surname><given-names>D.</given-names></name>; <name><surname>Vinyals</surname><given-names>O.</given-names></name>; <name><surname>Senior</surname><given-names>A. W.</given-names></name>; <name><surname>Kavukcuoglu</surname><given-names>K.</given-names></name>; <name><surname>Kohli</surname><given-names>P.</given-names></name>; <name><surname>Hassabis</surname><given-names>D.</given-names></name><article-title>Highly accurate protein
structure prediction with AlphaFold</article-title>. <source>NATURE</source><year>2021</year>, <volume>596</volume>, <fpage>583</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>.<pub-id pub-id-type="pmid">34265844</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Thiessen</surname><given-names>P. A.</given-names></name>; <name><surname>Bolton</surname><given-names>E. E.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Fu</surname><given-names>G.</given-names></name>; <name><surname>Gindulyte</surname><given-names>A.</given-names></name>; <name><surname>Han</surname><given-names>L.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>S.</given-names></name>; <name><surname>Shoemaker</surname><given-names>B. A.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Yu</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Bryant</surname><given-names>S. H.</given-names></name><article-title>PubChem
Substance and Compound databases</article-title>. <source>NUCLEIC ACIDS
RES</source><year>2016</year>, <volume>44</volume>, <fpage>D1202</fpage>–<lpage>D1213</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id>.<pub-id pub-id-type="pmid">26400175</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Bellis</surname><given-names>L. J.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>Davies</surname><given-names>M.</given-names></name>; <name><surname>Krüger</surname><given-names>F. A.</given-names></name>; <name><surname>Light</surname><given-names>Y.</given-names></name>; <name><surname>Mak</surname><given-names>L.</given-names></name>; <name><surname>McGlinchey</surname><given-names>S.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; <name><surname>Papadatos</surname><given-names>G.</given-names></name>; <name><surname>Santos</surname><given-names>R.</given-names></name>; <name><surname>Overington</surname><given-names>J. P.</given-names></name><article-title>The ChEMBL
bioactivity database:
an update</article-title>. <source>NUCLEIC ACIDS RES</source><year>2014</year>, <volume>42</volume>, <fpage>D1083</fpage>–<lpage>D1090</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1031</pub-id>.<pub-id pub-id-type="pmid">24214965</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Pence</surname><given-names>H. E.</given-names></name>; <name><surname>Williams</surname><given-names>A.</given-names></name><article-title>ChemSpider: An Online
Chemical Information Resource</article-title>. <source>J. CHEM EDUC</source><year>2010</year>, <volume>87</volume>, <fpage>1123</fpage>–<lpage>1124</lpage>. <pub-id pub-id-type="doi">10.1021/ed100697w</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Tang</surname><given-names>K. G.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Dandarchuluun</surname><given-names>C.</given-names></name>; <name><surname>Wong</surname><given-names>B. R.</given-names></name>; <name><surname>Khurelbaatar</surname><given-names>M.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Mayfield</surname><given-names>J.</given-names></name>; <name><surname>Sayle</surname><given-names>R. A.</given-names></name><article-title>ZINC20-A Free Ultralarge-Scale
Chemical Database for
Ligand Discovery</article-title>. <source>J. CHEM INF MODEL</source><year>2020</year>, <volume>60</volume>, <fpage>6065</fpage>–<lpage>6073</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00675</pub-id>.<pub-id pub-id-type="pmid">33118813</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Wishart</surname><given-names>D. S.</given-names></name>; <name><surname>Feunang</surname><given-names>Y. D.</given-names></name>; <name><surname>Guo</surname><given-names>A. C.</given-names></name>; <name><surname>Lo</surname><given-names>E. J.</given-names></name>; <name><surname>Marcu</surname><given-names>A.</given-names></name>; <name><surname>Grant</surname><given-names>J. R.</given-names></name>; <name><surname>Sajed</surname><given-names>T.</given-names></name>; <name><surname>Johnson</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Sayeeda</surname><given-names>Z.</given-names></name>; <name><surname>Assempour</surname><given-names>N.</given-names></name>; <name><surname>Iynkkaran</surname><given-names>I.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Maciejewski</surname><given-names>A.</given-names></name>; <name><surname>Gale</surname><given-names>N.</given-names></name>; <name><surname>Wilson</surname><given-names>A.</given-names></name>; <name><surname>Chin</surname><given-names>L.</given-names></name>; <name><surname>Cummings</surname><given-names>R.</given-names></name>; <name><surname>Le</surname><given-names>D.</given-names></name>; <name><surname>Pon</surname><given-names>A.</given-names></name>; <name><surname>Knox</surname><given-names>C.</given-names></name>; <name><surname>Wilson</surname><given-names>M.</given-names></name><article-title>DrugBank 5.0: a major
update to the DrugBank database
for 2018</article-title>. <source>NUCLEIC ACIDS RES</source><year>2018</year>, <volume>46</volume>, <fpage>D1074</fpage>–<lpage>D1082</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="book" id="cit11"><person-group person-group-type="allauthors"><name><surname>Tang</surname><given-names>B.</given-names></name>; <name><surname>Ewalt</surname><given-names>J.</given-names></name>; <name><surname>Ng</surname><given-names>H.</given-names></name></person-group><article-title>Generative AI
Models for Drug Discovery</article-title>. In <source>Biophysical
and Computational Tools in Drug Discovery</source>; <person-group person-group-type="editor"><name><surname>Saxena</surname><given-names>A. K.</given-names></name></person-group>, Ed.; <publisher-name>Springer
International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2021</year>; pp <fpage>221</fpage>–<lpage>243</lpage>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D.</given-names></name>; <name><surname>Bezrukov</surname><given-names>D.</given-names></name>; <name><surname>Zagribelnyy</surname><given-names>B.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V.</given-names></name>; <name><surname>Kamya</surname><given-names>P.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Ren</surname><given-names>F.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>Chemistry42:
An AI-Driven Platform for Molecular Design
and Optimization</article-title>. <source>J. CHEM INF MODEL</source><year>2023</year>, <volume>63</volume>, <fpage>695</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.2c01191</pub-id>.<pub-id pub-id-type="pmid">36728505</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Veselov</surname><given-names>M. S.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V. A.</given-names></name>; <name><surname>Aladinskaya</surname><given-names>A. V.</given-names></name>; <name><surname>Terentiev</surname><given-names>V. A.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D. A.</given-names></name>; <name><surname>Kuznetsov</surname><given-names>M. D.</given-names></name>; <name><surname>Asadulaev</surname><given-names>A.</given-names></name>; <name><surname>Volkov</surname><given-names>Y.</given-names></name>; <name><surname>Zholus</surname><given-names>A.</given-names></name>; <name><surname>Shayakhmetov</surname><given-names>R. R.</given-names></name>; <name><surname>Zhebrak</surname><given-names>A.</given-names></name>; <name><surname>Minaeva</surname><given-names>L. I.</given-names></name>; <name><surname>Zagribelnyy</surname><given-names>B. A.</given-names></name>; <name><surname>Lee</surname><given-names>L. H.</given-names></name>; <name><surname>Soll</surname><given-names>R.</given-names></name>; <name><surname>Madge</surname><given-names>D.</given-names></name>; <name><surname>Xing</surname><given-names>L.</given-names></name>; <name><surname>Guo</surname><given-names>T.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name><article-title>Deep learning enables rapid identification of potent
DDR1 kinase inhibitors</article-title>. <source>NAT BIOTECHNOL</source><year>2019</year>, <volume>37</volume>, <fpage>1038</fpage>–<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-019-0224-x</pub-id>.<pub-id pub-id-type="pmid">31477924</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="undeclared" id="cit14"><person-group person-group-type="allauthors"><name><surname>Lowe</surname><given-names>D.</given-names></name></person-group><source>Chemical reactions from
US patents (1976-Sep2016)</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://figshare.com/articles/dataset/Chemical_reactions_from_US_patents_1976-Sep2016_/5104873/1">https://figshare.com/articles/dataset/Chemical_reactions_from_US_patents_1976-Sep2016_/5104873/1</uri> (accessed Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Sadybekov</surname><given-names>A. A.</given-names></name>; <name><surname>Sadybekov</surname><given-names>A. V.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Iliopoulos-Tsoutsouvas</surname><given-names>C.</given-names></name>; <name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Pickett</surname><given-names>J.</given-names></name>; <name><surname>Houser</surname><given-names>B.</given-names></name>; <name><surname>Patel</surname><given-names>N.</given-names></name>; <name><surname>Tran</surname><given-names>N. K.</given-names></name>; <name><surname>Tong</surname><given-names>F.</given-names></name>; <name><surname>Zvonok</surname><given-names>N.</given-names></name>; <name><surname>Jain</surname><given-names>M. K.</given-names></name>; <name><surname>Savych</surname><given-names>O.</given-names></name>; <name><surname>Radchenko</surname><given-names>D. S.</given-names></name>; <name><surname>Nikas</surname><given-names>S. P.</given-names></name>; <name><surname>Petasis</surname><given-names>N. A.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Makriyannis</surname><given-names>A.</given-names></name>; <name><surname>Katritch</surname><given-names>V.</given-names></name><article-title>Synthon-based ligand discovery in
virtual libraries
of over 11 billion compounds</article-title>. <source>NATURE</source><year>2022</year>, <volume>601</volume>, <fpage>452</fpage>–<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-04220-9</pub-id>.<pub-id pub-id-type="pmid">34912117</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bellis</surname><given-names>L. J.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>Davies</surname><given-names>M.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Light</surname><given-names>Y.</given-names></name>; <name><surname>McGlinchey</surname><given-names>S.</given-names></name>; <name><surname>Michalovich</surname><given-names>D.</given-names></name>; <name><surname>Al-Lazikani</surname><given-names>B.</given-names></name>; <name><surname>Overington</surname><given-names>J. P.</given-names></name><article-title>ChEMBL:
a large-scale bioactivity database for drug discovery</article-title>. <source>NUCLEIC ACIDS RES</source><year>2012</year>, <volume>40</volume>, <fpage>D1100</fpage>–<lpage>D1107</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkr777</pub-id>.<pub-id pub-id-type="pmid">21948594</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Zdrazil</surname><given-names>B.</given-names></name>; <name><surname>Felix</surname><given-names>E.</given-names></name>; <name><surname>Hunter</surname><given-names>F.</given-names></name>; <name><surname>Manners</surname><given-names>E. J.</given-names></name>; <name><surname>Blackshaw</surname><given-names>J.</given-names></name>; <name><surname>Corbett</surname><given-names>S.</given-names></name>; <name><surname>de Veij</surname><given-names>M.</given-names></name>; <name><surname>Ioannidis</surname><given-names>H.</given-names></name>; <name><surname>Lopez</surname><given-names>D. M.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Magarinos</surname><given-names>M. P.</given-names></name>; <name><surname>Bosc</surname><given-names>N.</given-names></name>; <name><surname>Arcila</surname><given-names>R.</given-names></name>; <name><surname>Kiziloren</surname><given-names>T.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Adasme</surname><given-names>M. F.</given-names></name>; <name><surname>Monecke</surname><given-names>P.</given-names></name>; <name><surname>Landrum</surname><given-names>G. A.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name><article-title>The ChEMBL Database in 2023: a drug
discovery platform spanning multiple bioactivity data types and time
periods</article-title>. <source>NUCLEIC ACIDS RES</source><year>2024</year>, <volume>52</volume>, <fpage>D1180</fpage>–<lpage>D1192</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkad1004</pub-id>.<pub-id pub-id-type="pmid">37933841</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="weblink" id="cit18"><person-group><collab>ChemBridge</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chembridge.com/">https://chembridge.com/</uri> (accessed
Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="weblink" id="cit19"><person-group><collab>ChemDiv</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chemdiv.com/catalog/screening-libraries/">https://www.chemdiv.com/catalog/screening-libraries/</uri> (accessed Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="weblink" id="cit20"><person-group><collab>Chemspace</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chem-space.com/">https://chem-space.com/</uri> (accessed
Jun. 16, 2023).</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="weblink" id="cit21"><person-group><collab>Enamine</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://enamine.net/compound-collections/screening-collection">https://enamine.net/compound-collections/screening-collection</uri> (accessed Mar. 26, 2024).</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="weblink" id="cit22"><person-group><collab>Enamine Covalent
Compounds</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://enamine.net/compound-collections/covalent-compounds">https://enamine.net/compound-collections/covalent-compounds</uri> (accessed Jun. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="weblink" id="cit23"><person-group><collab>IBS Interbioscreen</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ibscreen.com/bases">https://www.ibscreen.com/bases</uri> (accessed Jun. 18, 2023).</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Tang</surname><given-names>K. G.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Dandarchuluun</surname><given-names>C.</given-names></name>; <name><surname>Wong</surname><given-names>B. R.</given-names></name>; <name><surname>Khurelbaatar</surname><given-names>M.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Mayfield</surname><given-names>J.</given-names></name>; <name><surname>Sayle</surname><given-names>R. A.</given-names></name><article-title>ZINC20—A
Free Ultralarge-Scale Chemical Database
for Ligand Discovery</article-title>. <source>J. CHEM INF MODEL</source><year>2020</year>, <volume>60</volume>, <fpage>6065</fpage>–<lpage>6073</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00675</pub-id>.<pub-id pub-id-type="pmid">33118813</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Shultz</surname><given-names>M. D.</given-names></name><article-title>Two Decades
under the Influence of the Rule of Five and the Changing Properties
of Approved Oral Drugs</article-title>. <source>J. MED CHEM</source><year>2019</year>, <volume>62</volume>, <fpage>1701</fpage>–<lpage>1714</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00686</pub-id>.<pub-id pub-id-type="pmid">30212196</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Huth</surname><given-names>J. R.</given-names></name>; <name><surname>Mendoza</surname><given-names>R.</given-names></name>; <name><surname>Olejniczak</surname><given-names>E. T.</given-names></name>; <name><surname>Johnson</surname><given-names>R. W.</given-names></name>; <name><surname>Cothron</surname><given-names>D. A.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Lerner</surname><given-names>C. G.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Hajduk</surname><given-names>P. J.</given-names></name><article-title>ALARM NMR: a rapid
and robust experimental method to detect reactive false positives
in biochemical screens</article-title>. <source>J. AM CHEM SOC</source><year>2005</year>, <volume>127</volume>, <fpage>217</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1021/ja0455547</pub-id>.<pub-id pub-id-type="pmid">15631471</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Agrawal</surname><given-names>A.</given-names></name>; <name><surname>Johnson</surname><given-names>S. L.</given-names></name>; <name><surname>Jacobsen</surname><given-names>J. A.</given-names></name>; <name><surname>Miller</surname><given-names>M. T.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Pellecchia</surname><given-names>M.</given-names></name>; <name><surname>Cohen</surname><given-names>S. M.</given-names></name><article-title>Chelator Fragment Libraries for Targeting
Metalloproteinases</article-title>. <source>CHEMMEDCHEM</source><year>2010</year>, <volume>5</volume>, <fpage>195</fpage>–<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200900516</pub-id>.<pub-id pub-id-type="pmid">20058293</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Baell</surname><given-names>J. B.</given-names></name>; <name><surname>Holloway</surname><given-names>G. A.</given-names></name><article-title>New Substructure
Filters for Removal of Pan Assay Interference
Compounds (PAINS) from Screening Libraries and for Their Exclusion
in Bioassays</article-title>. <source>J. MED CHEM</source><year>2010</year>, <volume>53</volume>, <fpage>2719</fpage>–<lpage>2740</lpage>. <pub-id pub-id-type="doi">10.1021/jm901137j</pub-id>.<pub-id pub-id-type="pmid">20131845</pub-id></mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Benigni</surname><given-names>R.</given-names></name>; <name><surname>Bossa</surname><given-names>C.</given-names></name><article-title>Structure alerts for
carcinogenicity, and the Salmonella assay system:
a novel insight through the chemical relational databases technology</article-title>. <source>MUTAT RES-FUND MOL M</source><year>2008</year>, <volume>659</volume>, <fpage>248</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrrev.2008.05.003</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Ashby</surname><given-names>J.</given-names></name>; <name><surname>Tennant</surname><given-names>R. W.</given-names></name><article-title>Chemical structure, Salmonella mutagenicity
and extent
of carcinogenicity as indicators of genotoxic carcinogenesis among
222 chemicals tested in rodents by the U.S. NCI/NTP</article-title>. <source>Mutation Research/Genetic Toxicology</source><year>1988</year>, <volume>204</volume>, <fpage>17</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/0165-1218(88)90114-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Kazius</surname><given-names>J.</given-names></name>; <name><surname>McGuire</surname><given-names>R.</given-names></name>; <name><surname>Bursi</surname><given-names>R.</given-names></name><article-title>Derivation
and Validation of Toxicophores
for Mutagenicity Prediction</article-title>. <source>J. MED CHEM</source><year>2005</year>, <volume>48</volume>, <fpage>312</fpage>–<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1021/jm040835a</pub-id>.<pub-id pub-id-type="pmid">15634026</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Bailey</surname><given-names>A. B.</given-names></name>; <name><surname>Chanderbhan</surname><given-names>R.</given-names></name>; <name><surname>Collazo-Braier</surname><given-names>N.</given-names></name>; <name><surname>Cheeseman</surname><given-names>M. A.</given-names></name>; <name><surname>Twaroski</surname><given-names>M. L.</given-names></name><article-title>The use of structure–activity
relationship analysis
in the food contact notification program</article-title>. <source>REGUL
TOXICOL PHARM</source><year>2005</year>, <volume>42</volume>, <fpage>225</fpage>–<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2005.04.006</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Brenk</surname><given-names>R.</given-names></name>; <name><surname>Schipani</surname><given-names>A.</given-names></name>; <name><surname>James</surname><given-names>D.</given-names></name>; <name><surname>Krasowski</surname><given-names>A.</given-names></name>; <name><surname>Gilbert</surname><given-names>I. H.</given-names></name>; <name><surname>Frearson</surname><given-names>J.</given-names></name>; <name><surname>Wyatt</surname><given-names>P. G.</given-names></name><article-title>Lessons learnt from
assembling screening libraries for drug discovery for neglected diseases</article-title>. <source>CHEMMEDCHEM</source><year>2008</year>, <volume>3</volume>, <fpage>435</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200700139</pub-id>.<pub-id pub-id-type="pmid">18064617</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Sushko</surname><given-names>I.</given-names></name>; <name><surname>Salmina</surname><given-names>E.</given-names></name>; <name><surname>Potemkin</surname><given-names>V. A.</given-names></name>; <name><surname>Poda</surname><given-names>G.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name><article-title>ToxAlerts:
A Web Server of Structural Alerts for Toxic Chemicals and Compounds
with Potential Adverse Reactions</article-title>. <source>J. CHEM INF
MODEL</source><year>2012</year>, <volume>52</volume>, <fpage>2310</fpage>–<lpage>2316</lpage>. <pub-id pub-id-type="doi">10.1021/ci300245q</pub-id>.<pub-id pub-id-type="pmid">22876798</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11040716</article-id>
    <article-id pub-id-type="pmid">38563534</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.3c01979</article-id>
    <article-categories>
      <subj-group>
        <subject>Application Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MolProphet: A One-Stop,
General Purpose, and AI-Based
Platform for the Early Stages of Drug Discovery</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-9368-9737</contrib-id>
        <name>
          <surname>Yang</surname>
          <given-names>Keda</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Xie</surname>
          <given-names>Zewen</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Li</surname>
          <given-names>Zhen</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <name>
          <surname>Qian</surname>
          <given-names>Xiaoliang</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Sun</surname>
          <given-names>Nannan</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath6">
        <name>
          <surname>He</surname>
          <given-names>Tao</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath7">
        <name>
          <surname>Xu</surname>
          <given-names>Zuodong</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath8">
        <name>
          <surname>Jiang</surname>
          <given-names>Jing</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath9">
        <name>
          <surname>Mei</surname>
          <given-names>Qi</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath10">
        <name>
          <surname>Wang</surname>
          <given-names>Jie</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath11">
        <name>
          <surname>Qu</surname>
          <given-names>Shugang</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath12">
        <name>
          <surname>Xu</surname>
          <given-names>Xiaoling</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath13">
        <name>
          <surname>Chen</surname>
          <given-names>Chaoxiang</given-names>
        </name>
        <xref rid="cor2" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath14">
        <name>
          <surname>Ju</surname>
          <given-names>Bin</given-names>
        </name>
        <xref rid="cor3" ref-type="other">*</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Key
Laboratory of Artificial Organs and Computational Medicine in Zhejiang
Province, Shulan International Medical College, <institution>Zhejiang Shuren University</institution>, Hangzhou 310015, <country>P. R. China</country></aff>
      <aff id="aff2"><label>‡</label><institution>Hangzhou
SanOmics Information Technology Co., Ltd.</institution>, Hangzhou 310015, <country>P. R. China</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label><email>ziyao1988@zju.edu.cn</email>.</corresp>
      <corresp id="cor2"><label>*</label><email>ccx@zjsru.edu.cn</email>.</corresp>
      <corresp id="cor3"><label>*</label><email>jubin_hz@163.com</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>02</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>22</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <volume>64</volume>
    <issue>8</issue>
    <fpage>2941</fpage>
    <lpage>2947</lpage>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>21</day>
        <month>03</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>20</day>
        <month>03</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0004" id="ab-tgr1"/>
      </p>
      <p>Artificial intelligence
(AI) is an effective tool to
accelerate
drug discovery and cut costs in discovery processes. Many successful
AI applications are reported in the early stages of small molecule
drug discovery. However, most of those applications require a deep
understanding of software and hardware, and focus on a single field
that implies data normalization and transfer between those applications
is still a challenge for normal users. It usually limits the application
of AI in drug discovery. Here, based on a series of robust models,
we formed a one-stop, general purpose, and AI-based drug discovery
platform, MolProphet, to provide complete functionalities in the early
stages of small molecule drug discovery, including AI-based target
pocket prediction, hit discovery and lead optimization, and compound
targeting, as well as abundant analyzing tools to check the results.
MolProphet is an accessible and user-friendly web-based platform that
is fully designed according to the practices in the drug discovery
industry. The molecule screened, generated, or optimized by the MolProphet
is purchasable and synthesizable at low cost but with good drug-likeness.
More than 400 users from industry and academia have used MolProphet
in their work. We hope this platform can provide a powerful solution
to assist each normal researcher in drug design and related research
areas. It is available for everyone at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Ministry of Science and Technology of the People''s Republic of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100002855</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>G2022016010L</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Scientific Research Fund of Zhejiang Provincial Education Department</institution>
            <institution-id institution-id-type="doi">NA</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>Y202352312</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Zhejiang Health Information Association Research Program</institution>
            <institution-id institution-id-type="doi">NA</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2023XHSZ-Z05</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Fundamental Research Funds for the Central Universities</institution>
            <institution-id institution-id-type="doi">10.13039/501100012226</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022ZFJH003</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Zhejiang Province</institution>
            <institution-id institution-id-type="doi">10.13039/501100004731</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>LD22H300004</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci3c01979</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci3c01979</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>AI
(artificial intelligence)
has the potential to significantly
accelerate the process of bringing new drugs to market, while also
reducing the costs and risks involved in drug development.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> A lot of AI tools, such as DeepChem,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Deep Docking,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> DeepPocket,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and AlphaFold,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> have
been developed and increasingly used in the discovery process, especially
in the discovery of small molecule drugs. However, most of those applications
still require a deep understanding of software and hardware and focus
on a single field that implies data normalization and transfer between
those applications, which are still challenges for normal researchers.
On the other side, the high cost of the hardware and software of AI/computational
chemistry is sometimes a barrier to many researchers and startups
to manipulate the power of AI to accelerate their drug discovery projects.</p>
    <p>The success of virtual screening (VS) in drug discovery depends
on the availability and quality of the compound library as well as
the accuracy and validation of the computational methods used. Hence,
building and curating a diverse and representative compound library
are crucial for identifying lead compounds with potential pharmacological
activities. A compound database is indispensable in performing AI-based
VS. Many databases were created to provide the SMILES of compounds,
for example, PubChem,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> ChEMBL,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> ChemSpider,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Zinc,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Drugbank,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and so
on, to perform structure-based virtual screening (SBVS) and ligand-based
virtual screening (LBVS). But, voluminous data are difficult to process,
and there is a need for specialized skills and computational resources
for data retrieval and utilization. Additionally, differences in data
naming and formatting across databases may require extra data processing
and formatting.</p>
    <p>The chemical space may contain 1 × 10<sup>60</sup> molecules.
It would be more productive if candidate molecules are generated,
rather than screened from libraries, with suitable absorption, distribution,
metabolism, excretion, and toxicity (ADMET) properties as prerequisites
at the beginning of the molecule design process.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> AI molecule generation models are widely used for designing
drug candidates using prior biological and chemical knowledge in drug
discovery.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> By using a combination of AI
generative techniques and reinforcement learning, Insilico Medicine
successfully created new discoidin domain receptor 1 (DDR1) kinase
inhibitors to treat fibrosis in only 21 days.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Despite all generated molecules being chemically meaningful, they
may be too difficult/expensive to synthesize and have poor drug-like
properties. In practice, only very few results generated by AI are
synthesized and tested in a wet experiment, due to the potential value
of this molecule being smaller than the cost to synthesize that molecule.</p>
    <p>To remove the barriers in using AI technology, integrating multicompound
databases and generating molecules with good drug-like properties
and synthetic accessibility for normal researchers, we developed the
SaaS (Software as a Service) and cocreation platform MolProphet (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>). It aims to make AI technology more accessible to each investigator
who works in new drug discovery. The generated molecule in the results
is easy to synthesize, and the drug-likeness of each molecular is
accessed as well. MolProphet provides a one-stop, general purpose
online drug discovery platform to help investigators accelerate their
new drug development process. The platform mainly focuses on the early
stages of drug discovery, especially on hits discovery and the hits-to-leads
stage. In the following sections, we describe the key features of
the MolProphet platform.</p>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Implementation</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Framework of MolProphet</title>
      <p>The framework
of MolProphet is shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. This framework consists of a series of interconnected
modules and tools that collect protein and compound data, generate
molecules, and facilitate the analysis of biological data, prediction
of compound properties, and optimization of drug-like molecules. Initially,
the pocket discovery and management module enable the identification
and management of protein pockets. These pockets, once identified,
can be easily utilized by other key modules. Alternatively, if the
3D structure of the protein is not available, the framework allows
for starting from a reference molecule. Then, the framework provides
key modules such as structure-based or ligand-based screening, AI
molecule generation, AI docking, and optimization. These modules aid
in the discovery of potential small molecular structures. In the subsequent
steps, analysis tools are available to provide crucial data including
3D structure, binding mode, drug-likeness, synthetic pathway, and
more. This data assists researchers in selecting potential molecules
for further investigation. Moreover, the selected or starred molecules
can undergo verification through wet experiments. Finally, the molecules
identified through experiment can be further optimized within the
software framework, forming a closed loop. At the same time, experimental
data can be used to fine-tune the software models, enhancing the predictive,
screening, and generating capabilities in subsequent iterations.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Framework
of the AI-based drug discovery platform MolProphet.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0001" id="gr1" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec2.2">
    <label>3</label>
    <title>Key Modules</title>
    <p>The theoretical background
and methods of key modules are briefly
introduced in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>. The functions of these key modules are outlined below.</p>
    <sec id="sec2.2.1">
      <label>3.1</label>
      <title>Pocket Discovery and Management Module</title>
      <p>In the process
of new drug development, finding the correct target
pocket structure can greatly improve the development efficiency. This
module is designed to help users quickly define pocket structures
as the basis for subsequent molecular screening, design, optimization,
and evaluation. The platform uses deep learning algorithms to automatically
predict one to five most competitive pocket structures for each protein
and form a 3D visual selection interface. Besides automated pocket
prediction, the pockets can be established by defining a set of key
amino acid residues manually at first. Then, a set of self-developed
intelligent algorithms automatically completes the pocket structures.
Furthermore, the module creates an associated profile for each pocket
that can be viewed and recalled at any time. In addition, more functions,
such as defining the pocket structure precisely to each amino acid
site, etc., will be added to the module in the future to suit the
needs of different application scenarios. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> shows a sample output of pocket identification.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Output
of pocket prediction and definition module (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="6X1A">6X1A</ext-link>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0002" id="gr2" position="float"/>
      </fig>
      <p>Data from wet lab experiments on target pockets
can be uploaded
and utilized to fine-tune the pretrained activity prediction model.
The refined activity prediction model will then be employed for molecular
ranking in subsequent screening, generation, and optimization tasks.</p>
    </sec>
    <sec id="sec2.2.2">
      <label>3.2</label>
      <title>Structure-Based Drug Discovery Module</title>
      <p>In
order to reduce the synthesis costs in the early stages of drug
discovery, commercial purchasable compound libraries are usually screened
in the industry. But the traditional CADD virtual screening method
has been suffering from slow screening efficiency. Therefore, this
module aims to quickly complete the virtual screening of commercially
purchasable compound libraries by AI technology. The core of this
module is a deep neural network, trained by using 18 million real
bioassay data to predict the affinity between targets and ligands.
It surpasses traditional techniques in terms of universal positive
rates and enrichment factors. Moreover, it has accomplished the screening
of a billion orders of magnitude molecules within a week. The screening
of tens of millions of molecules can be completed very quickly on
the online platform.</p>
    </sec>
    <sec id="sec2.2.3">
      <label>3.3</label>
      <title>Ligand-Based Drug Discovery
Module</title>
      <p>This module aims to quickly retrieve molecules similar
to known molecules
in commercial libraries through AI algorithms. It includes a 2D structure
similarity algorithm (the output result has high similarity in the
molecular structure), which enables the retrieval of millions of molecular
data in 1 min by using a 2D structure based on graphical neural network
representation and the vector search Milvus algorithm. The 3D pharmacophore
similarity algorithm (the output result has high structural variation)
is included as well, and it can code 3D features for 1 billion molecules
in 1 day.</p>
    </sec>
    <sec id="sec2.2.4">
      <label>3.4</label>
      <title>AI Molecular Generative
Module</title>
      <p>This
module aims to generate novel, low-cost, and easily synthesized molecules
using AI technology. Unlike many AI molecule generation algorithms
that primarily focus on activity without considering drug-like properties
and synthesizability, this module prioritizes drug-likeness, ease
of synthesis, and cost-effectiveness as core indicators. It directly
generates molecules from procurable building blocks and provides a
synthesis solution for each generated molecule. The synthesis solution
includes the top 300 most frequently used reaction templates from
over 1000 known reaction templates,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> based
on more than 3 million explicit examples and expert-selected templates.
Additionally, over 500,000 procurable building blocks<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> are prepared to match these templates, enabling efficient
and accessible synthesis of the desired molecules. In practice, 70%
of AI generated molecules can be synthesized within 3–4 steps
under simple reaction conditions by cheap building blocks. A sample
case of a synthetic pathway and template is shown in Figures S13 and
S14 of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>, respectively.</p>
    </sec>
    <sec id="sec2.2.5">
      <label>3.5</label>
      <title>Molecule Optimization Modules</title>
      <p>Molecular
optimization modules are powerful tools that enable users to optimize
molecules using a variety of methods. One of the key features of the
module is its ability to optimize molecules by scaffold hopping, fragment,
and R-group. This means that users can select the optimization method
that best suits their needs, whether they want to optimize the entire
molecule or only specific portions of it.</p>
      <p>By using the scaffold
hopping optimization method, the molecular optimization module will
optimize the entire structure of the molecule, making it more stable
and potentially more effective. This method is particularly useful
for users who work with small molecules or compounds with simple structures.</p>
      <p>Alternatively, users can choose to optimize their molecules by
fragment. This method focuses on optimizing the core structure of
the molecule while leaving the peripheral groups intact. This is particularly
useful for users who are working with molecules that have complex
peripheral structures but a simple core.</p>
      <p>Finally, the R-group
optimization method is designed for users
who want to optimize specific R groups of their molecules. This method
enables users to optimize individual R-groups within a molecule while
leaving the rest of the structure intact. This is particularly useful
for users who work with complex molecules with multiple functional
R-groups.</p>
    </sec>
    <sec id="sec2.2.6">
      <label>3.6</label>
      <title>AI Docking Module</title>
      <p>This module aims
to help practitioners perform rapid evaluation of a molecular data
set (usually ligand-based screening results or user-owned molecular
data set) through AI technology. Based on geometric deep learning,
it learns target pocket information and small molecule structure information;
reinforcement learning is used to sample the receptor flexible conformation
while optimizing the binding conformation of the ligand molecule to
predict the minimum free energy of molecule binding to the target
pocket.</p>
    </sec>
  </sec>
  <sec id="sec2.3">
    <label>4</label>
    <title>Integrated Compound Database</title>
    <p>Compound
databases are important for structural-based or ligand-based
virtual screening. The platform not only includes multipublic compound
databases but also includes compound data developed by ourselves. <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref> shows the details
of compound databases from public sources (CDPSs). <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> shows MolProphet ’s
target focused compound library (TFCL). There are about 3.98 billion
molecules in CDPSs. It should be noted that all compounds in CDPSs
are purchasable from the Web site of vendors. TFCL is selected from
CDPSs or generated by an AI model focused on the properties of compounds
with diversity, novelty, and accessibility. The TFCL was divided into
15 sublibraries with about total 1 M molecules. The molecules generated
by AI can be synthesized easily from building blocks. It should be
noted that only isomeric SMILES are stored in the TFCL and CDPSs.
The conformers are not stored in the database and generated by RDkit
from SMILES.</p>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <title>Compound Databases Integrated in the
Platform from Public Sources</title>
      </caption>
      <table frame="hsides" rules="groups" border="0">
        <colgroup>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead>
          <tr>
            <th style="border:none;" align="center">
              <bold>Public
Compound Databases</bold>
            </th>
            <th style="border:none;" align="center">
              <bold>Size</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td style="border:none;" align="left">TopScience</td>
            <td style="border:none;" align="left">7,272,880</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChEMBL<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></td>
            <td style="border:none;" align="left">2,136,186</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChEMBL Clinical<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></td>
            <td style="border:none;" align="left">5,014</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChemBridge<sup><xref ref-type="bibr" rid="ref18">18</xref></sup></td>
            <td style="border:none;" align="left">1,543,545</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Chemdiv<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></td>
            <td style="border:none;" align="left">1,601,800</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Chemspace<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></td>
            <td style="border:none;" align="left">6,078,492</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">DrugBank<sup><xref ref-type="bibr" rid="ref10">10</xref></sup></td>
            <td style="border:none;" align="left">2,709</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Selected from Enamine<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></td>
            <td style="border:none;" align="left">2,849,580</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Covalent Screening
Library<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></td>
            <td style="border:none;" align="left">11,199</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">InterBioScreen<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></td>
            <td style="border:none;" align="left">555,295</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ZINC<sup><xref ref-type="bibr" rid="ref24">24</xref></sup></td>
            <td style="border:none;" align="left">10,725,144</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Real
Space<sup><xref ref-type="bibr" rid="ref15">15</xref></sup></td>
            <td style="border:none;" align="left">3,900,000,000</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Diverse Structure
Molecules<sup><xref ref-type="bibr" rid="ref15">15</xref></sup></td>
            <td style="border:none;" align="left">48,232,770</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">
              <bold>Total</bold>
            </td>
            <td style="border:none;" align="left">
              <bold>3,981,014,614</bold>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="tbl2" position="float">
      <label>Table 2</label>
      <caption>
        <title>Target Focused Compound
Library from
MolProphet</title>
      </caption>
      <table frame="hsides" rules="groups" border="0">
        <colgroup>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead>
          <tr>
            <th style="border:none;" align="center">
              <bold>MolProphet’s
Target Focused Compound Library</bold>
            </th>
            <th style="border:none;" align="center">
              <bold>Size</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td style="border:none;" align="left">Clinical
and marketed libraries</td>
            <td style="border:none;" align="left">15030</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Natural product libraries</td>
            <td style="border:none;" align="left">35058</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Signaling pathway related
libraries</td>
            <td style="border:none;" align="left">188000</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Macrocyclic compound
library</td>
            <td style="border:none;" align="left">355455</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Anti-infection
and antivirus
libraries</td>
            <td style="border:none;" align="left">39153</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Highly selective
inhibitor
libraries</td>
            <td style="border:none;" align="left">40943</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Cell death related
libraries</td>
            <td style="border:none;" align="left">50870</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Antitumor compound
library</td>
            <td style="border:none;" align="left">53775</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Immune/Inflammatory
molecule
compound library</td>
            <td style="border:none;" align="left">40985</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Anticardiovascular
disease
compound library</td>
            <td style="border:none;" align="left">10846</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Antiaging compound
library</td>
            <td style="border:none;" align="left">30051</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Phenotypic screening
library</td>
            <td style="border:none;" align="left">52242</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Protease inhibitor
library</td>
            <td style="border:none;" align="left">6468</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Covalent inhibitor
library</td>
            <td style="border:none;" align="left">10846</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Metabolic related
libraries</td>
            <td style="border:none;" align="left">38392</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">
              <bold>Total</bold>
            </td>
            <td style="border:none;" align="left">
              <bold>968114</bold>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </sec>
  <sec id="sec2.4">
    <label>5</label>
    <title>Analysis Tools</title>
    <sec id="sec2.4.1">
      <label>5.1</label>
      <title>Oral Bioavailability Assessment
and Structural
Alerts</title>
      <p>During small molecule drug design, the Lipinski’s
rule of 5<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> is often used to evaluate oral
bioavailability of a compound. As shown in Figure S8 of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>, the platform evaluates
the compound by physicochemical properties such as molecular weight,
topological polar surface area, lipophilicity, and hydrogen bond donors/acceptors.</p>
      <p>In addition to the rule of 5 evaluation, it is important to identify
and address structural alerts in the proposed drug molecule. Structural
alerts are functional groups or substructures that have been associated
with toxicity or poor bioavailability in previous drug development
studies. By identifying and removing structural alerts in the design
phase, drug discovery teams can increase the chances of success in
clinical trials and decrease the risk of late-stage attritions due
to safety or efficacy concerns. Here, we provide BMS Rule,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Chelator Rule,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> PAINS
Rule,<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Genotoxic Carcinogenicity Rule,<sup><xref ref-type="bibr" rid="ref29">29</xref>−<xref ref-type="bibr" rid="ref32">32</xref></sup> NTD Rule,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> and SureChEMBL Rule<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> structural alerts.</p>
    </sec>
    <sec id="sec2.4.2">
      <label>5.2</label>
      <title>ADMET
Prediction</title>
      <p>ADMET prediction
is a crucial aspect of drug discovery and development. ADMET prediction
plays a vital role in predicting the safety and efficacy of a drug
before it is tested in clinical trials, which helps to reduce the
risk of drug failure and ensures patient safety. In the platform, <italic>Absorption</italic> is assessed by Caco2, Human Intestinal Absorption
(HIA), and P-glycoprotein (P-gp) Inhibitor. <italic>Bioavailability</italic> is assessed by Hydration Free Energy (HFE), Distribution, Blood-Brain
Barrier (BBB) Penetration, Plasma Protein Binding Ratio (PPBR), and
Volume of Distribution (VDSS). <italic>Metabolism</italic> is assessed
by CYP2D6 Inhibitor, CYP3A4 Inhibitor, CYP2C9 Inhibitor, CYP2D6 Substrate,
CYP3A4 Substrate, CYP2C9 Substrate, CYP2C19 Inhibitor, and CYP1A2
Inhibitor. Excretion is assessed by Half Life (hour) and Clearance
(mL/min/g). <italic>Toxicity</italic> is assessed by hERG, Drug-induced
Liver Injury (DILI), Aryl hydrocarbon Receptor (NR-AhR), Carcinogencity,
Median Lethal Dose (LD<sub>50</sub>), Respiratory toxicity, and Eye
Corrosion. The databases and methods used in ADMET prediction are
listed in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>.</p>
    </sec>
    <sec id="sec2.4.3">
      <label>5.3</label>
      <title>Binding Mode Assessment</title>
      <p>To rapidly
analyze the interaction characteristics between molecules and ligands,
the interactions present in different ways: (1) a 3D viewer of protein
and ligand (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a) [A 3D viewer of protein ligand allows researchers to visualize
and explore the spatial arrangement between a protein and a ligand
molecule. It provides valuable insights for drug design and optimization.];
(2) binding mode analysis (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b), i.e., the interactions between ligand and receptor
represented by different colors depend on the type of force; and (3)
binding site analysis (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>c), i.e., statistical analysis of binding sites for the possible
conformations of ligands. The vertical coordinate is the number of
ligand conformations predicted by AI, and the horizontal coordinate
is the amino acid site; different color statistics correspond to different
types of binding forces, and the statistics represent the number of
conformations where the current ligand has a binding force with that
amino acid site. More analysis tools such as toxic substructure hints,
generation of proprietary molecular reports, etc. will be added to
this module in the future.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>(a) 3D viewer of the protein and ligand, (b)
binding mode of the
ligand-protein, and (c) the analysis of interaction of the residue.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec2.5">
    <label>6</label>
    <title>Others</title>
    <sec id="sec2.5.1">
      <label>6.1</label>
      <title>User
Interface</title>
      <p>Recognizing that not
all users possess expertise in drug discovery software, the MolProphet
platform was carefully developed to ensure user-friendliness, minimizing
any potential hurdles. Each functional module within the system has
been streamlined to require just a few simple clicks, and every step
is accompanied by helpful hints to guide the users. This intuitive
design approach empowers ordinary users to swiftly navigate the platform
and effectively carry out projects, even without prior experience.</p>
      <p>Moreover, the MolProphet platform has preset multitype input data
methods for all modules (such as defining target pockets, submitting
reference molecules, etc.) to meet different usage scenarios. For
instance, when defining target pockets, users have the option to upload
local files for instant processing or search for standard PDB files
using PDB IDs sourced from the official PDB Web site (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</uri>). Similarly,
when setting reference molecules, users can choose from multiple options,
including direct molecular structure drawing, uploading local files,
inputting SMILES, or reading collection records. These flexible input
methods empower users to conveniently tailor their interactions with
the platform based on their specific needs.</p>
      <p>For result management,
the MolProphet platform provides task objectives
and conclusion record functions for each task, which provides convenience
for later review and also facilitates communication among users. Users
can also freely collect, download, and delete the results to meet
the needs of different scenarios. For each specific result molecule,
depending on the task, a corresponding result analysis interface is
provided, which can be viewed by clicking on the corresponding molecule
tab.</p>
      <p>In the future, the MolProphet platform will add more content
related
to results and records, including but not limited to automatically
generated task reports, molecular reports, experimental record management,
etc.</p>
    </sec>
    <sec id="sec2.5.2">
      <label>6.2</label>
      <title>Management System</title>
      <p>For project management,
the MolProphet platform establishes a set of project-based data management
solutions to solve users’ data management problems. Users can
create multiple projects with data isolated from each other. Each
project can invite different users to collaborate and share information
with the project. The platform also establishes an independent three-level
management system (PI, administrator, and general members) for each
project, which is convenient for users to manage their own research
teams.</p>
      <p>In terms of task management, users can check the progress
of tasks at any time while they are in progress, and they are also
allowed to cancel tasks that are in queue or in progress and to retry
at any time if there is an abnormality in the task (in some scenarios,
retrying can solve the abnormality). However, to avoid management
confusion, the platform restricts users from managing only the tasks
they have created.</p>
      <p>On the other hand, the platform separately
establishes a hybrid
cloud system for teams or companies with higher requirements of privacy
and confidentiality (e.g., pharmaceutical companies and research teams
with corresponding needs, etc.). It enables the instant distribution
of the latest models from the public cloud and ensures the security
of private cloud data.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>7</label>
    <title>Applications</title>
    <p>The
development of MolProphet
started in 2017, and since then,
the platform has been used in more than 20 hit discovery and lead
optimization projects with impressive results. The SaaS platform has
more than 400 users and has served in more than 600 projects until
today (December 10, 2023). The platform has been successful in identifying
compounds at the micromolar level, which have been further optimized
to achieve nanomolar levels. More details of application cases are
provided in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>.</p>
  </sec>
  <sec id="sec4">
    <label>8</label>
    <title>Conclusion</title>
    <p>MolProphet is a one-stop,
general purpose, and AI-based platform
for the early stages of small molecule drug discovery. It aims to
provide AI-based drug discovery tools to each normal researcher in
drug discovery. With MolProphet, users can access the platform from
anywhere, eliminating the need for a complex hardware or software
setup. Even without extensive knowledge in computational aid drug
discovery and AI, researchers in drug discovery can easily harness
the power of AIDD (AI-assisted drug discovery) to accelerate their
work.</p>
    <p>According to the practice in the industry, the platform
offers
a comprehensive suite of AI-based drug discovery tools for the early
stages of drug development. These include virtual screening, molecular
generation, and optimization functions. Our patented molecule generation
approach allows for direct generation of molecules from building blocks,
resulting in compounds with enhanced drug-likeness but easier and
cheaper to synthesize. The compound results from the virtual screening
are purchasable. In the optimization modules, the compounds can be
optimized by scaffold hopping, fragment, and R-group, which are valuable
for lead optimization.</p>
    <p>In summary, MolProphet is a valuable
online AIDD tool that empowers
researchers to accelerate their work in the early stages of small
molecule drug development.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes-2">
    <title>Data Availability Statement</title>
    <p>The software
is publicly available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>. Many modules, including virtual screening, are freely accessible
to all users. Trial software licenses can be provided to interested
readers. Data for training the models is constructed from publicly
available sources such as ChEMBL (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/">https://www.ebi.ac.uk/chembl/</uri>).</p>
  </notes>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting
Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.3c01979?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.3c01979</ext-link>.<list id="silist" list-type="simple"><list-item><p>1. Test application case
on MolProphet, 2. Software
technology framework of MolProphet, 3. Methods and the theoretical
background of modules, 4. Stability of AI molecule generation, 5.
Databases and methods used in ADMET prediction, 6. Fine-tune modules
with wet-lab experimental data, 7. The original images of <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_si_001.pdf">
        <caption>
          <p>ci3c01979_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e747-autogenerated">
    <p>The authors declare no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work is
supported by the Fundamental
Research Funds for
the Central Universities, grant No. 2022ZFJH003, the Ministry of Science
and Technology of the People’s Republic of China (No. G2022016010L),
the Scientific Research Fund of Zhejiang Provincial Education Department
(No. Y202352312), the Zhejiang Health Information Association Research
Program (No. 2023XHSZ-Z05), and the Natural Science Foundation of
Zhejiang Province (No. LD22H300004).</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Paul</surname><given-names>D.</given-names></name>; <name><surname>Sanap</surname><given-names>G.</given-names></name>; <name><surname>Shenoy</surname><given-names>S.</given-names></name>; <name><surname>Kalyane</surname><given-names>D.</given-names></name>; <name><surname>Kalia</surname><given-names>K.</given-names></name>; <name><surname>Tekade</surname><given-names>R. K.</given-names></name><article-title>Artificial intelligence
in drug discovery and development</article-title>. <source>DRUG DISCOV
TODAY</source><year>2021</year>, <volume>26</volume>, <fpage>80</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.10.010</pub-id>.<pub-id pub-id-type="pmid">33099022</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="book" id="cit2"><person-group person-group-type="allauthors"><name><surname>Ramsundar</surname><given-names>B.</given-names></name>; <name><surname>Eastman</surname><given-names>P.</given-names></name>; <name><surname>Walters</surname><given-names>P.</given-names></name>; <name><surname>Pande</surname><given-names>V.</given-names></name>; <name><surname>Leswing</surname><given-names>K.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name></person-group><source>Deep Learning for the Life Sciences</source>; <publisher-name>O’Reilly Media</publisher-name>: <year>2019</year>.</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Gentile</surname><given-names>F.</given-names></name>; <name><surname>Agrawal</surname><given-names>V.</given-names></name>; <name><surname>Hsing</surname><given-names>M.</given-names></name>; <name><surname>Ton</surname><given-names>A.</given-names></name>; <name><surname>Ban</surname><given-names>F.</given-names></name>; <name><surname>Norinder</surname><given-names>U.</given-names></name>; <name><surname>Gleave</surname><given-names>M. E.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name><article-title>Deep Docking:
A Deep Learning Platform for Augmentation of Structure Based Drug
Discovery</article-title>. <source>ACS CENTRAL SCI</source><year>2020</year>, <volume>6</volume>, <fpage>939</fpage>–<lpage>949</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.0c00229</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Aggarwal</surname><given-names>R.</given-names></name>; <name><surname>Gupta</surname><given-names>A.</given-names></name>; <name><surname>Chelur</surname><given-names>V.</given-names></name>; <name><surname>Jawahar</surname><given-names>C. V.</given-names></name>; <name><surname>Priyakumar</surname><given-names>U. D.</given-names></name><article-title>DeepPocket:
Ligand Binding Site Detection and Segmentation using 3D Convolutional
Neural Networks</article-title>. <source>J. CHEM INF MODEL</source><year>2022</year>, <volume>62</volume>, <fpage>5069</fpage>–<lpage>5079</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00799</pub-id>.<pub-id pub-id-type="pmid">34374539</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Jumper</surname><given-names>J.</given-names></name>; <name><surname>Evans</surname><given-names>R.</given-names></name>; <name><surname>Pritzel</surname><given-names>A.</given-names></name>; <name><surname>Green</surname><given-names>T.</given-names></name>; <name><surname>Figurnov</surname><given-names>M.</given-names></name>; <name><surname>Ronneberger</surname><given-names>O.</given-names></name>; <name><surname>Tunyasuvunakool</surname><given-names>K.</given-names></name>; <name><surname>Bates</surname><given-names>R.</given-names></name>; <name><surname>Žídek</surname><given-names>A.</given-names></name>; <name><surname>Potapenko</surname><given-names>A.</given-names></name>; <name><surname>Bridgland</surname><given-names>A.</given-names></name>; <name><surname>Meyer</surname><given-names>C.</given-names></name>; <name><surname>Kohl</surname><given-names>S. A. A.</given-names></name>; <name><surname>Ballard</surname><given-names>A. J.</given-names></name>; <name><surname>Cowie</surname><given-names>A.</given-names></name>; <name><surname>Romera-Paredes</surname><given-names>B.</given-names></name>; <name><surname>Nikolov</surname><given-names>S.</given-names></name>; <name><surname>Jain</surname><given-names>R.</given-names></name>; <name><surname>Adler</surname><given-names>J.</given-names></name>; <name><surname>Back</surname><given-names>T.</given-names></name>; <name><surname>Petersen</surname><given-names>S.</given-names></name>; <name><surname>Reiman</surname><given-names>D.</given-names></name>; <name><surname>Clancy</surname><given-names>E.</given-names></name>; <name><surname>Zielinski</surname><given-names>M.</given-names></name>; <name><surname>Steinegger</surname><given-names>M.</given-names></name>; <name><surname>Pacholska</surname><given-names>M.</given-names></name>; <name><surname>Berghammer</surname><given-names>T.</given-names></name>; <name><surname>Bodenstein</surname><given-names>S.</given-names></name>; <name><surname>Silver</surname><given-names>D.</given-names></name>; <name><surname>Vinyals</surname><given-names>O.</given-names></name>; <name><surname>Senior</surname><given-names>A. W.</given-names></name>; <name><surname>Kavukcuoglu</surname><given-names>K.</given-names></name>; <name><surname>Kohli</surname><given-names>P.</given-names></name>; <name><surname>Hassabis</surname><given-names>D.</given-names></name><article-title>Highly accurate protein
structure prediction with AlphaFold</article-title>. <source>NATURE</source><year>2021</year>, <volume>596</volume>, <fpage>583</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>.<pub-id pub-id-type="pmid">34265844</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Thiessen</surname><given-names>P. A.</given-names></name>; <name><surname>Bolton</surname><given-names>E. E.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Fu</surname><given-names>G.</given-names></name>; <name><surname>Gindulyte</surname><given-names>A.</given-names></name>; <name><surname>Han</surname><given-names>L.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>S.</given-names></name>; <name><surname>Shoemaker</surname><given-names>B. A.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Yu</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Bryant</surname><given-names>S. H.</given-names></name><article-title>PubChem
Substance and Compound databases</article-title>. <source>NUCLEIC ACIDS
RES</source><year>2016</year>, <volume>44</volume>, <fpage>D1202</fpage>–<lpage>D1213</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id>.<pub-id pub-id-type="pmid">26400175</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Bellis</surname><given-names>L. J.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>Davies</surname><given-names>M.</given-names></name>; <name><surname>Krüger</surname><given-names>F. A.</given-names></name>; <name><surname>Light</surname><given-names>Y.</given-names></name>; <name><surname>Mak</surname><given-names>L.</given-names></name>; <name><surname>McGlinchey</surname><given-names>S.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; <name><surname>Papadatos</surname><given-names>G.</given-names></name>; <name><surname>Santos</surname><given-names>R.</given-names></name>; <name><surname>Overington</surname><given-names>J. P.</given-names></name><article-title>The ChEMBL
bioactivity database:
an update</article-title>. <source>NUCLEIC ACIDS RES</source><year>2014</year>, <volume>42</volume>, <fpage>D1083</fpage>–<lpage>D1090</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1031</pub-id>.<pub-id pub-id-type="pmid">24214965</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Pence</surname><given-names>H. E.</given-names></name>; <name><surname>Williams</surname><given-names>A.</given-names></name><article-title>ChemSpider: An Online
Chemical Information Resource</article-title>. <source>J. CHEM EDUC</source><year>2010</year>, <volume>87</volume>, <fpage>1123</fpage>–<lpage>1124</lpage>. <pub-id pub-id-type="doi">10.1021/ed100697w</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Tang</surname><given-names>K. G.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Dandarchuluun</surname><given-names>C.</given-names></name>; <name><surname>Wong</surname><given-names>B. R.</given-names></name>; <name><surname>Khurelbaatar</surname><given-names>M.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Mayfield</surname><given-names>J.</given-names></name>; <name><surname>Sayle</surname><given-names>R. A.</given-names></name><article-title>ZINC20-A Free Ultralarge-Scale
Chemical Database for
Ligand Discovery</article-title>. <source>J. CHEM INF MODEL</source><year>2020</year>, <volume>60</volume>, <fpage>6065</fpage>–<lpage>6073</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00675</pub-id>.<pub-id pub-id-type="pmid">33118813</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Wishart</surname><given-names>D. S.</given-names></name>; <name><surname>Feunang</surname><given-names>Y. D.</given-names></name>; <name><surname>Guo</surname><given-names>A. C.</given-names></name>; <name><surname>Lo</surname><given-names>E. J.</given-names></name>; <name><surname>Marcu</surname><given-names>A.</given-names></name>; <name><surname>Grant</surname><given-names>J. R.</given-names></name>; <name><surname>Sajed</surname><given-names>T.</given-names></name>; <name><surname>Johnson</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Sayeeda</surname><given-names>Z.</given-names></name>; <name><surname>Assempour</surname><given-names>N.</given-names></name>; <name><surname>Iynkkaran</surname><given-names>I.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Maciejewski</surname><given-names>A.</given-names></name>; <name><surname>Gale</surname><given-names>N.</given-names></name>; <name><surname>Wilson</surname><given-names>A.</given-names></name>; <name><surname>Chin</surname><given-names>L.</given-names></name>; <name><surname>Cummings</surname><given-names>R.</given-names></name>; <name><surname>Le</surname><given-names>D.</given-names></name>; <name><surname>Pon</surname><given-names>A.</given-names></name>; <name><surname>Knox</surname><given-names>C.</given-names></name>; <name><surname>Wilson</surname><given-names>M.</given-names></name><article-title>DrugBank 5.0: a major
update to the DrugBank database
for 2018</article-title>. <source>NUCLEIC ACIDS RES</source><year>2018</year>, <volume>46</volume>, <fpage>D1074</fpage>–<lpage>D1082</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="book" id="cit11"><person-group person-group-type="allauthors"><name><surname>Tang</surname><given-names>B.</given-names></name>; <name><surname>Ewalt</surname><given-names>J.</given-names></name>; <name><surname>Ng</surname><given-names>H.</given-names></name></person-group><article-title>Generative AI
Models for Drug Discovery</article-title>. In <source>Biophysical
and Computational Tools in Drug Discovery</source>; <person-group person-group-type="editor"><name><surname>Saxena</surname><given-names>A. K.</given-names></name></person-group>, Ed.; <publisher-name>Springer
International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2021</year>; pp <fpage>221</fpage>–<lpage>243</lpage>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D.</given-names></name>; <name><surname>Bezrukov</surname><given-names>D.</given-names></name>; <name><surname>Zagribelnyy</surname><given-names>B.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V.</given-names></name>; <name><surname>Kamya</surname><given-names>P.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Ren</surname><given-names>F.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>Chemistry42:
An AI-Driven Platform for Molecular Design
and Optimization</article-title>. <source>J. CHEM INF MODEL</source><year>2023</year>, <volume>63</volume>, <fpage>695</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.2c01191</pub-id>.<pub-id pub-id-type="pmid">36728505</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Veselov</surname><given-names>M. S.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V. A.</given-names></name>; <name><surname>Aladinskaya</surname><given-names>A. V.</given-names></name>; <name><surname>Terentiev</surname><given-names>V. A.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D. A.</given-names></name>; <name><surname>Kuznetsov</surname><given-names>M. D.</given-names></name>; <name><surname>Asadulaev</surname><given-names>A.</given-names></name>; <name><surname>Volkov</surname><given-names>Y.</given-names></name>; <name><surname>Zholus</surname><given-names>A.</given-names></name>; <name><surname>Shayakhmetov</surname><given-names>R. R.</given-names></name>; <name><surname>Zhebrak</surname><given-names>A.</given-names></name>; <name><surname>Minaeva</surname><given-names>L. I.</given-names></name>; <name><surname>Zagribelnyy</surname><given-names>B. A.</given-names></name>; <name><surname>Lee</surname><given-names>L. H.</given-names></name>; <name><surname>Soll</surname><given-names>R.</given-names></name>; <name><surname>Madge</surname><given-names>D.</given-names></name>; <name><surname>Xing</surname><given-names>L.</given-names></name>; <name><surname>Guo</surname><given-names>T.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name><article-title>Deep learning enables rapid identification of potent
DDR1 kinase inhibitors</article-title>. <source>NAT BIOTECHNOL</source><year>2019</year>, <volume>37</volume>, <fpage>1038</fpage>–<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-019-0224-x</pub-id>.<pub-id pub-id-type="pmid">31477924</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="undeclared" id="cit14"><person-group person-group-type="allauthors"><name><surname>Lowe</surname><given-names>D.</given-names></name></person-group><source>Chemical reactions from
US patents (1976-Sep2016)</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://figshare.com/articles/dataset/Chemical_reactions_from_US_patents_1976-Sep2016_/5104873/1">https://figshare.com/articles/dataset/Chemical_reactions_from_US_patents_1976-Sep2016_/5104873/1</uri> (accessed Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Sadybekov</surname><given-names>A. A.</given-names></name>; <name><surname>Sadybekov</surname><given-names>A. V.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Iliopoulos-Tsoutsouvas</surname><given-names>C.</given-names></name>; <name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Pickett</surname><given-names>J.</given-names></name>; <name><surname>Houser</surname><given-names>B.</given-names></name>; <name><surname>Patel</surname><given-names>N.</given-names></name>; <name><surname>Tran</surname><given-names>N. K.</given-names></name>; <name><surname>Tong</surname><given-names>F.</given-names></name>; <name><surname>Zvonok</surname><given-names>N.</given-names></name>; <name><surname>Jain</surname><given-names>M. K.</given-names></name>; <name><surname>Savych</surname><given-names>O.</given-names></name>; <name><surname>Radchenko</surname><given-names>D. S.</given-names></name>; <name><surname>Nikas</surname><given-names>S. P.</given-names></name>; <name><surname>Petasis</surname><given-names>N. A.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Makriyannis</surname><given-names>A.</given-names></name>; <name><surname>Katritch</surname><given-names>V.</given-names></name><article-title>Synthon-based ligand discovery in
virtual libraries
of over 11 billion compounds</article-title>. <source>NATURE</source><year>2022</year>, <volume>601</volume>, <fpage>452</fpage>–<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-04220-9</pub-id>.<pub-id pub-id-type="pmid">34912117</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bellis</surname><given-names>L. J.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>Davies</surname><given-names>M.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Light</surname><given-names>Y.</given-names></name>; <name><surname>McGlinchey</surname><given-names>S.</given-names></name>; <name><surname>Michalovich</surname><given-names>D.</given-names></name>; <name><surname>Al-Lazikani</surname><given-names>B.</given-names></name>; <name><surname>Overington</surname><given-names>J. P.</given-names></name><article-title>ChEMBL:
a large-scale bioactivity database for drug discovery</article-title>. <source>NUCLEIC ACIDS RES</source><year>2012</year>, <volume>40</volume>, <fpage>D1100</fpage>–<lpage>D1107</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkr777</pub-id>.<pub-id pub-id-type="pmid">21948594</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Zdrazil</surname><given-names>B.</given-names></name>; <name><surname>Felix</surname><given-names>E.</given-names></name>; <name><surname>Hunter</surname><given-names>F.</given-names></name>; <name><surname>Manners</surname><given-names>E. J.</given-names></name>; <name><surname>Blackshaw</surname><given-names>J.</given-names></name>; <name><surname>Corbett</surname><given-names>S.</given-names></name>; <name><surname>de Veij</surname><given-names>M.</given-names></name>; <name><surname>Ioannidis</surname><given-names>H.</given-names></name>; <name><surname>Lopez</surname><given-names>D. M.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Magarinos</surname><given-names>M. P.</given-names></name>; <name><surname>Bosc</surname><given-names>N.</given-names></name>; <name><surname>Arcila</surname><given-names>R.</given-names></name>; <name><surname>Kiziloren</surname><given-names>T.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Adasme</surname><given-names>M. F.</given-names></name>; <name><surname>Monecke</surname><given-names>P.</given-names></name>; <name><surname>Landrum</surname><given-names>G. A.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name><article-title>The ChEMBL Database in 2023: a drug
discovery platform spanning multiple bioactivity data types and time
periods</article-title>. <source>NUCLEIC ACIDS RES</source><year>2024</year>, <volume>52</volume>, <fpage>D1180</fpage>–<lpage>D1192</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkad1004</pub-id>.<pub-id pub-id-type="pmid">37933841</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="weblink" id="cit18"><person-group><collab>ChemBridge</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chembridge.com/">https://chembridge.com/</uri> (accessed
Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="weblink" id="cit19"><person-group><collab>ChemDiv</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chemdiv.com/catalog/screening-libraries/">https://www.chemdiv.com/catalog/screening-libraries/</uri> (accessed Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="weblink" id="cit20"><person-group><collab>Chemspace</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chem-space.com/">https://chem-space.com/</uri> (accessed
Jun. 16, 2023).</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="weblink" id="cit21"><person-group><collab>Enamine</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://enamine.net/compound-collections/screening-collection">https://enamine.net/compound-collections/screening-collection</uri> (accessed Mar. 26, 2024).</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="weblink" id="cit22"><person-group><collab>Enamine Covalent
Compounds</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://enamine.net/compound-collections/covalent-compounds">https://enamine.net/compound-collections/covalent-compounds</uri> (accessed Jun. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="weblink" id="cit23"><person-group><collab>IBS Interbioscreen</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ibscreen.com/bases">https://www.ibscreen.com/bases</uri> (accessed Jun. 18, 2023).</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Tang</surname><given-names>K. G.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Dandarchuluun</surname><given-names>C.</given-names></name>; <name><surname>Wong</surname><given-names>B. R.</given-names></name>; <name><surname>Khurelbaatar</surname><given-names>M.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Mayfield</surname><given-names>J.</given-names></name>; <name><surname>Sayle</surname><given-names>R. A.</given-names></name><article-title>ZINC20—A
Free Ultralarge-Scale Chemical Database
for Ligand Discovery</article-title>. <source>J. CHEM INF MODEL</source><year>2020</year>, <volume>60</volume>, <fpage>6065</fpage>–<lpage>6073</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00675</pub-id>.<pub-id pub-id-type="pmid">33118813</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Shultz</surname><given-names>M. D.</given-names></name><article-title>Two Decades
under the Influence of the Rule of Five and the Changing Properties
of Approved Oral Drugs</article-title>. <source>J. MED CHEM</source><year>2019</year>, <volume>62</volume>, <fpage>1701</fpage>–<lpage>1714</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00686</pub-id>.<pub-id pub-id-type="pmid">30212196</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Huth</surname><given-names>J. R.</given-names></name>; <name><surname>Mendoza</surname><given-names>R.</given-names></name>; <name><surname>Olejniczak</surname><given-names>E. T.</given-names></name>; <name><surname>Johnson</surname><given-names>R. W.</given-names></name>; <name><surname>Cothron</surname><given-names>D. A.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Lerner</surname><given-names>C. G.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Hajduk</surname><given-names>P. J.</given-names></name><article-title>ALARM NMR: a rapid
and robust experimental method to detect reactive false positives
in biochemical screens</article-title>. <source>J. AM CHEM SOC</source><year>2005</year>, <volume>127</volume>, <fpage>217</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1021/ja0455547</pub-id>.<pub-id pub-id-type="pmid">15631471</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Agrawal</surname><given-names>A.</given-names></name>; <name><surname>Johnson</surname><given-names>S. L.</given-names></name>; <name><surname>Jacobsen</surname><given-names>J. A.</given-names></name>; <name><surname>Miller</surname><given-names>M. T.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Pellecchia</surname><given-names>M.</given-names></name>; <name><surname>Cohen</surname><given-names>S. M.</given-names></name><article-title>Chelator Fragment Libraries for Targeting
Metalloproteinases</article-title>. <source>CHEMMEDCHEM</source><year>2010</year>, <volume>5</volume>, <fpage>195</fpage>–<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200900516</pub-id>.<pub-id pub-id-type="pmid">20058293</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Baell</surname><given-names>J. B.</given-names></name>; <name><surname>Holloway</surname><given-names>G. A.</given-names></name><article-title>New Substructure
Filters for Removal of Pan Assay Interference
Compounds (PAINS) from Screening Libraries and for Their Exclusion
in Bioassays</article-title>. <source>J. MED CHEM</source><year>2010</year>, <volume>53</volume>, <fpage>2719</fpage>–<lpage>2740</lpage>. <pub-id pub-id-type="doi">10.1021/jm901137j</pub-id>.<pub-id pub-id-type="pmid">20131845</pub-id></mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Benigni</surname><given-names>R.</given-names></name>; <name><surname>Bossa</surname><given-names>C.</given-names></name><article-title>Structure alerts for
carcinogenicity, and the Salmonella assay system:
a novel insight through the chemical relational databases technology</article-title>. <source>MUTAT RES-FUND MOL M</source><year>2008</year>, <volume>659</volume>, <fpage>248</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrrev.2008.05.003</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Ashby</surname><given-names>J.</given-names></name>; <name><surname>Tennant</surname><given-names>R. W.</given-names></name><article-title>Chemical structure, Salmonella mutagenicity
and extent
of carcinogenicity as indicators of genotoxic carcinogenesis among
222 chemicals tested in rodents by the U.S. NCI/NTP</article-title>. <source>Mutation Research/Genetic Toxicology</source><year>1988</year>, <volume>204</volume>, <fpage>17</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/0165-1218(88)90114-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Kazius</surname><given-names>J.</given-names></name>; <name><surname>McGuire</surname><given-names>R.</given-names></name>; <name><surname>Bursi</surname><given-names>R.</given-names></name><article-title>Derivation
and Validation of Toxicophores
for Mutagenicity Prediction</article-title>. <source>J. MED CHEM</source><year>2005</year>, <volume>48</volume>, <fpage>312</fpage>–<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1021/jm040835a</pub-id>.<pub-id pub-id-type="pmid">15634026</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Bailey</surname><given-names>A. B.</given-names></name>; <name><surname>Chanderbhan</surname><given-names>R.</given-names></name>; <name><surname>Collazo-Braier</surname><given-names>N.</given-names></name>; <name><surname>Cheeseman</surname><given-names>M. A.</given-names></name>; <name><surname>Twaroski</surname><given-names>M. L.</given-names></name><article-title>The use of structure–activity
relationship analysis
in the food contact notification program</article-title>. <source>REGUL
TOXICOL PHARM</source><year>2005</year>, <volume>42</volume>, <fpage>225</fpage>–<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2005.04.006</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Brenk</surname><given-names>R.</given-names></name>; <name><surname>Schipani</surname><given-names>A.</given-names></name>; <name><surname>James</surname><given-names>D.</given-names></name>; <name><surname>Krasowski</surname><given-names>A.</given-names></name>; <name><surname>Gilbert</surname><given-names>I. H.</given-names></name>; <name><surname>Frearson</surname><given-names>J.</given-names></name>; <name><surname>Wyatt</surname><given-names>P. G.</given-names></name><article-title>Lessons learnt from
assembling screening libraries for drug discovery for neglected diseases</article-title>. <source>CHEMMEDCHEM</source><year>2008</year>, <volume>3</volume>, <fpage>435</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200700139</pub-id>.<pub-id pub-id-type="pmid">18064617</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Sushko</surname><given-names>I.</given-names></name>; <name><surname>Salmina</surname><given-names>E.</given-names></name>; <name><surname>Potemkin</surname><given-names>V. A.</given-names></name>; <name><surname>Poda</surname><given-names>G.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name><article-title>ToxAlerts:
A Web Server of Structural Alerts for Toxic Chemicals and Compounds
with Potential Adverse Reactions</article-title>. <source>J. CHEM INF
MODEL</source><year>2012</year>, <volume>52</volume>, <fpage>2310</fpage>–<lpage>2316</lpage>. <pub-id pub-id-type="doi">10.1021/ci300245q</pub-id>.<pub-id pub-id-type="pmid">22876798</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11040716</article-id>
    <article-id pub-id-type="pmid">38563534</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.3c01979</article-id>
    <article-categories>
      <subj-group>
        <subject>Application Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MolProphet: A One-Stop,
General Purpose, and AI-Based
Platform for the Early Stages of Drug Discovery</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-9368-9737</contrib-id>
        <name>
          <surname>Yang</surname>
          <given-names>Keda</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Xie</surname>
          <given-names>Zewen</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Li</surname>
          <given-names>Zhen</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <name>
          <surname>Qian</surname>
          <given-names>Xiaoliang</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Sun</surname>
          <given-names>Nannan</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath6">
        <name>
          <surname>He</surname>
          <given-names>Tao</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath7">
        <name>
          <surname>Xu</surname>
          <given-names>Zuodong</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath8">
        <name>
          <surname>Jiang</surname>
          <given-names>Jing</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath9">
        <name>
          <surname>Mei</surname>
          <given-names>Qi</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath10">
        <name>
          <surname>Wang</surname>
          <given-names>Jie</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath11">
        <name>
          <surname>Qu</surname>
          <given-names>Shugang</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath12">
        <name>
          <surname>Xu</surname>
          <given-names>Xiaoling</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath13">
        <name>
          <surname>Chen</surname>
          <given-names>Chaoxiang</given-names>
        </name>
        <xref rid="cor2" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath14">
        <name>
          <surname>Ju</surname>
          <given-names>Bin</given-names>
        </name>
        <xref rid="cor3" ref-type="other">*</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Key
Laboratory of Artificial Organs and Computational Medicine in Zhejiang
Province, Shulan International Medical College, <institution>Zhejiang Shuren University</institution>, Hangzhou 310015, <country>P. R. China</country></aff>
      <aff id="aff2"><label>‡</label><institution>Hangzhou
SanOmics Information Technology Co., Ltd.</institution>, Hangzhou 310015, <country>P. R. China</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label><email>ziyao1988@zju.edu.cn</email>.</corresp>
      <corresp id="cor2"><label>*</label><email>ccx@zjsru.edu.cn</email>.</corresp>
      <corresp id="cor3"><label>*</label><email>jubin_hz@163.com</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>02</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>22</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <volume>64</volume>
    <issue>8</issue>
    <fpage>2941</fpage>
    <lpage>2947</lpage>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>21</day>
        <month>03</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>20</day>
        <month>03</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0004" id="ab-tgr1"/>
      </p>
      <p>Artificial intelligence
(AI) is an effective tool to
accelerate
drug discovery and cut costs in discovery processes. Many successful
AI applications are reported in the early stages of small molecule
drug discovery. However, most of those applications require a deep
understanding of software and hardware, and focus on a single field
that implies data normalization and transfer between those applications
is still a challenge for normal users. It usually limits the application
of AI in drug discovery. Here, based on a series of robust models,
we formed a one-stop, general purpose, and AI-based drug discovery
platform, MolProphet, to provide complete functionalities in the early
stages of small molecule drug discovery, including AI-based target
pocket prediction, hit discovery and lead optimization, and compound
targeting, as well as abundant analyzing tools to check the results.
MolProphet is an accessible and user-friendly web-based platform that
is fully designed according to the practices in the drug discovery
industry. The molecule screened, generated, or optimized by the MolProphet
is purchasable and synthesizable at low cost but with good drug-likeness.
More than 400 users from industry and academia have used MolProphet
in their work. We hope this platform can provide a powerful solution
to assist each normal researcher in drug design and related research
areas. It is available for everyone at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Ministry of Science and Technology of the People''s Republic of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100002855</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>G2022016010L</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Scientific Research Fund of Zhejiang Provincial Education Department</institution>
            <institution-id institution-id-type="doi">NA</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>Y202352312</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Zhejiang Health Information Association Research Program</institution>
            <institution-id institution-id-type="doi">NA</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2023XHSZ-Z05</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Fundamental Research Funds for the Central Universities</institution>
            <institution-id institution-id-type="doi">10.13039/501100012226</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022ZFJH003</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Zhejiang Province</institution>
            <institution-id institution-id-type="doi">10.13039/501100004731</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>LD22H300004</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci3c01979</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci3c01979</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>AI
(artificial intelligence)
has the potential to significantly
accelerate the process of bringing new drugs to market, while also
reducing the costs and risks involved in drug development.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> A lot of AI tools, such as DeepChem,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Deep Docking,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> DeepPocket,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and AlphaFold,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> have
been developed and increasingly used in the discovery process, especially
in the discovery of small molecule drugs. However, most of those applications
still require a deep understanding of software and hardware and focus
on a single field that implies data normalization and transfer between
those applications, which are still challenges for normal researchers.
On the other side, the high cost of the hardware and software of AI/computational
chemistry is sometimes a barrier to many researchers and startups
to manipulate the power of AI to accelerate their drug discovery projects.</p>
    <p>The success of virtual screening (VS) in drug discovery depends
on the availability and quality of the compound library as well as
the accuracy and validation of the computational methods used. Hence,
building and curating a diverse and representative compound library
are crucial for identifying lead compounds with potential pharmacological
activities. A compound database is indispensable in performing AI-based
VS. Many databases were created to provide the SMILES of compounds,
for example, PubChem,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> ChEMBL,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> ChemSpider,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Zinc,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Drugbank,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and so
on, to perform structure-based virtual screening (SBVS) and ligand-based
virtual screening (LBVS). But, voluminous data are difficult to process,
and there is a need for specialized skills and computational resources
for data retrieval and utilization. Additionally, differences in data
naming and formatting across databases may require extra data processing
and formatting.</p>
    <p>The chemical space may contain 1 × 10<sup>60</sup> molecules.
It would be more productive if candidate molecules are generated,
rather than screened from libraries, with suitable absorption, distribution,
metabolism, excretion, and toxicity (ADMET) properties as prerequisites
at the beginning of the molecule design process.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> AI molecule generation models are widely used for designing
drug candidates using prior biological and chemical knowledge in drug
discovery.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> By using a combination of AI
generative techniques and reinforcement learning, Insilico Medicine
successfully created new discoidin domain receptor 1 (DDR1) kinase
inhibitors to treat fibrosis in only 21 days.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Despite all generated molecules being chemically meaningful, they
may be too difficult/expensive to synthesize and have poor drug-like
properties. In practice, only very few results generated by AI are
synthesized and tested in a wet experiment, due to the potential value
of this molecule being smaller than the cost to synthesize that molecule.</p>
    <p>To remove the barriers in using AI technology, integrating multicompound
databases and generating molecules with good drug-like properties
and synthetic accessibility for normal researchers, we developed the
SaaS (Software as a Service) and cocreation platform MolProphet (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>). It aims to make AI technology more accessible to each investigator
who works in new drug discovery. The generated molecule in the results
is easy to synthesize, and the drug-likeness of each molecular is
accessed as well. MolProphet provides a one-stop, general purpose
online drug discovery platform to help investigators accelerate their
new drug development process. The platform mainly focuses on the early
stages of drug discovery, especially on hits discovery and the hits-to-leads
stage. In the following sections, we describe the key features of
the MolProphet platform.</p>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Implementation</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Framework of MolProphet</title>
      <p>The framework
of MolProphet is shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. This framework consists of a series of interconnected
modules and tools that collect protein and compound data, generate
molecules, and facilitate the analysis of biological data, prediction
of compound properties, and optimization of drug-like molecules. Initially,
the pocket discovery and management module enable the identification
and management of protein pockets. These pockets, once identified,
can be easily utilized by other key modules. Alternatively, if the
3D structure of the protein is not available, the framework allows
for starting from a reference molecule. Then, the framework provides
key modules such as structure-based or ligand-based screening, AI
molecule generation, AI docking, and optimization. These modules aid
in the discovery of potential small molecular structures. In the subsequent
steps, analysis tools are available to provide crucial data including
3D structure, binding mode, drug-likeness, synthetic pathway, and
more. This data assists researchers in selecting potential molecules
for further investigation. Moreover, the selected or starred molecules
can undergo verification through wet experiments. Finally, the molecules
identified through experiment can be further optimized within the
software framework, forming a closed loop. At the same time, experimental
data can be used to fine-tune the software models, enhancing the predictive,
screening, and generating capabilities in subsequent iterations.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Framework
of the AI-based drug discovery platform MolProphet.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0001" id="gr1" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec2.2">
    <label>3</label>
    <title>Key Modules</title>
    <p>The theoretical background
and methods of key modules are briefly
introduced in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>. The functions of these key modules are outlined below.</p>
    <sec id="sec2.2.1">
      <label>3.1</label>
      <title>Pocket Discovery and Management Module</title>
      <p>In the process
of new drug development, finding the correct target
pocket structure can greatly improve the development efficiency. This
module is designed to help users quickly define pocket structures
as the basis for subsequent molecular screening, design, optimization,
and evaluation. The platform uses deep learning algorithms to automatically
predict one to five most competitive pocket structures for each protein
and form a 3D visual selection interface. Besides automated pocket
prediction, the pockets can be established by defining a set of key
amino acid residues manually at first. Then, a set of self-developed
intelligent algorithms automatically completes the pocket structures.
Furthermore, the module creates an associated profile for each pocket
that can be viewed and recalled at any time. In addition, more functions,
such as defining the pocket structure precisely to each amino acid
site, etc., will be added to the module in the future to suit the
needs of different application scenarios. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> shows a sample output of pocket identification.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Output
of pocket prediction and definition module (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="6X1A">6X1A</ext-link>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0002" id="gr2" position="float"/>
      </fig>
      <p>Data from wet lab experiments on target pockets
can be uploaded
and utilized to fine-tune the pretrained activity prediction model.
The refined activity prediction model will then be employed for molecular
ranking in subsequent screening, generation, and optimization tasks.</p>
    </sec>
    <sec id="sec2.2.2">
      <label>3.2</label>
      <title>Structure-Based Drug Discovery Module</title>
      <p>In
order to reduce the synthesis costs in the early stages of drug
discovery, commercial purchasable compound libraries are usually screened
in the industry. But the traditional CADD virtual screening method
has been suffering from slow screening efficiency. Therefore, this
module aims to quickly complete the virtual screening of commercially
purchasable compound libraries by AI technology. The core of this
module is a deep neural network, trained by using 18 million real
bioassay data to predict the affinity between targets and ligands.
It surpasses traditional techniques in terms of universal positive
rates and enrichment factors. Moreover, it has accomplished the screening
of a billion orders of magnitude molecules within a week. The screening
of tens of millions of molecules can be completed very quickly on
the online platform.</p>
    </sec>
    <sec id="sec2.2.3">
      <label>3.3</label>
      <title>Ligand-Based Drug Discovery
Module</title>
      <p>This module aims to quickly retrieve molecules similar
to known molecules
in commercial libraries through AI algorithms. It includes a 2D structure
similarity algorithm (the output result has high similarity in the
molecular structure), which enables the retrieval of millions of molecular
data in 1 min by using a 2D structure based on graphical neural network
representation and the vector search Milvus algorithm. The 3D pharmacophore
similarity algorithm (the output result has high structural variation)
is included as well, and it can code 3D features for 1 billion molecules
in 1 day.</p>
    </sec>
    <sec id="sec2.2.4">
      <label>3.4</label>
      <title>AI Molecular Generative
Module</title>
      <p>This
module aims to generate novel, low-cost, and easily synthesized molecules
using AI technology. Unlike many AI molecule generation algorithms
that primarily focus on activity without considering drug-like properties
and synthesizability, this module prioritizes drug-likeness, ease
of synthesis, and cost-effectiveness as core indicators. It directly
generates molecules from procurable building blocks and provides a
synthesis solution for each generated molecule. The synthesis solution
includes the top 300 most frequently used reaction templates from
over 1000 known reaction templates,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> based
on more than 3 million explicit examples and expert-selected templates.
Additionally, over 500,000 procurable building blocks<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> are prepared to match these templates, enabling efficient
and accessible synthesis of the desired molecules. In practice, 70%
of AI generated molecules can be synthesized within 3–4 steps
under simple reaction conditions by cheap building blocks. A sample
case of a synthetic pathway and template is shown in Figures S13 and
S14 of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>, respectively.</p>
    </sec>
    <sec id="sec2.2.5">
      <label>3.5</label>
      <title>Molecule Optimization Modules</title>
      <p>Molecular
optimization modules are powerful tools that enable users to optimize
molecules using a variety of methods. One of the key features of the
module is its ability to optimize molecules by scaffold hopping, fragment,
and R-group. This means that users can select the optimization method
that best suits their needs, whether they want to optimize the entire
molecule or only specific portions of it.</p>
      <p>By using the scaffold
hopping optimization method, the molecular optimization module will
optimize the entire structure of the molecule, making it more stable
and potentially more effective. This method is particularly useful
for users who work with small molecules or compounds with simple structures.</p>
      <p>Alternatively, users can choose to optimize their molecules by
fragment. This method focuses on optimizing the core structure of
the molecule while leaving the peripheral groups intact. This is particularly
useful for users who are working with molecules that have complex
peripheral structures but a simple core.</p>
      <p>Finally, the R-group
optimization method is designed for users
who want to optimize specific R groups of their molecules. This method
enables users to optimize individual R-groups within a molecule while
leaving the rest of the structure intact. This is particularly useful
for users who work with complex molecules with multiple functional
R-groups.</p>
    </sec>
    <sec id="sec2.2.6">
      <label>3.6</label>
      <title>AI Docking Module</title>
      <p>This module aims
to help practitioners perform rapid evaluation of a molecular data
set (usually ligand-based screening results or user-owned molecular
data set) through AI technology. Based on geometric deep learning,
it learns target pocket information and small molecule structure information;
reinforcement learning is used to sample the receptor flexible conformation
while optimizing the binding conformation of the ligand molecule to
predict the minimum free energy of molecule binding to the target
pocket.</p>
    </sec>
  </sec>
  <sec id="sec2.3">
    <label>4</label>
    <title>Integrated Compound Database</title>
    <p>Compound
databases are important for structural-based or ligand-based
virtual screening. The platform not only includes multipublic compound
databases but also includes compound data developed by ourselves. <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref> shows the details
of compound databases from public sources (CDPSs). <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> shows MolProphet ’s
target focused compound library (TFCL). There are about 3.98 billion
molecules in CDPSs. It should be noted that all compounds in CDPSs
are purchasable from the Web site of vendors. TFCL is selected from
CDPSs or generated by an AI model focused on the properties of compounds
with diversity, novelty, and accessibility. The TFCL was divided into
15 sublibraries with about total 1 M molecules. The molecules generated
by AI can be synthesized easily from building blocks. It should be
noted that only isomeric SMILES are stored in the TFCL and CDPSs.
The conformers are not stored in the database and generated by RDkit
from SMILES.</p>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <title>Compound Databases Integrated in the
Platform from Public Sources</title>
      </caption>
      <table frame="hsides" rules="groups" border="0">
        <colgroup>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead>
          <tr>
            <th style="border:none;" align="center">
              <bold>Public
Compound Databases</bold>
            </th>
            <th style="border:none;" align="center">
              <bold>Size</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td style="border:none;" align="left">TopScience</td>
            <td style="border:none;" align="left">7,272,880</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChEMBL<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></td>
            <td style="border:none;" align="left">2,136,186</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChEMBL Clinical<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></td>
            <td style="border:none;" align="left">5,014</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ChemBridge<sup><xref ref-type="bibr" rid="ref18">18</xref></sup></td>
            <td style="border:none;" align="left">1,543,545</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Chemdiv<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></td>
            <td style="border:none;" align="left">1,601,800</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Chemspace<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></td>
            <td style="border:none;" align="left">6,078,492</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">DrugBank<sup><xref ref-type="bibr" rid="ref10">10</xref></sup></td>
            <td style="border:none;" align="left">2,709</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Selected from Enamine<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></td>
            <td style="border:none;" align="left">2,849,580</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Covalent Screening
Library<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></td>
            <td style="border:none;" align="left">11,199</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">InterBioScreen<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></td>
            <td style="border:none;" align="left">555,295</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">ZINC<sup><xref ref-type="bibr" rid="ref24">24</xref></sup></td>
            <td style="border:none;" align="left">10,725,144</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Real
Space<sup><xref ref-type="bibr" rid="ref15">15</xref></sup></td>
            <td style="border:none;" align="left">3,900,000,000</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Enamine Diverse Structure
Molecules<sup><xref ref-type="bibr" rid="ref15">15</xref></sup></td>
            <td style="border:none;" align="left">48,232,770</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">
              <bold>Total</bold>
            </td>
            <td style="border:none;" align="left">
              <bold>3,981,014,614</bold>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="tbl2" position="float">
      <label>Table 2</label>
      <caption>
        <title>Target Focused Compound
Library from
MolProphet</title>
      </caption>
      <table frame="hsides" rules="groups" border="0">
        <colgroup>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead>
          <tr>
            <th style="border:none;" align="center">
              <bold>MolProphet’s
Target Focused Compound Library</bold>
            </th>
            <th style="border:none;" align="center">
              <bold>Size</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td style="border:none;" align="left">Clinical
and marketed libraries</td>
            <td style="border:none;" align="left">15030</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Natural product libraries</td>
            <td style="border:none;" align="left">35058</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Signaling pathway related
libraries</td>
            <td style="border:none;" align="left">188000</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Macrocyclic compound
library</td>
            <td style="border:none;" align="left">355455</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Anti-infection
and antivirus
libraries</td>
            <td style="border:none;" align="left">39153</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Highly selective
inhibitor
libraries</td>
            <td style="border:none;" align="left">40943</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Cell death related
libraries</td>
            <td style="border:none;" align="left">50870</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Antitumor compound
library</td>
            <td style="border:none;" align="left">53775</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Immune/Inflammatory
molecule
compound library</td>
            <td style="border:none;" align="left">40985</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Anticardiovascular
disease
compound library</td>
            <td style="border:none;" align="left">10846</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Antiaging compound
library</td>
            <td style="border:none;" align="left">30051</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Phenotypic screening
library</td>
            <td style="border:none;" align="left">52242</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Protease inhibitor
library</td>
            <td style="border:none;" align="left">6468</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Covalent inhibitor
library</td>
            <td style="border:none;" align="left">10846</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">Metabolic related
libraries</td>
            <td style="border:none;" align="left">38392</td>
          </tr>
          <tr>
            <td style="border:none;" align="left">
              <bold>Total</bold>
            </td>
            <td style="border:none;" align="left">
              <bold>968114</bold>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </sec>
  <sec id="sec2.4">
    <label>5</label>
    <title>Analysis Tools</title>
    <sec id="sec2.4.1">
      <label>5.1</label>
      <title>Oral Bioavailability Assessment
and Structural
Alerts</title>
      <p>During small molecule drug design, the Lipinski’s
rule of 5<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> is often used to evaluate oral
bioavailability of a compound. As shown in Figure S8 of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>, the platform evaluates
the compound by physicochemical properties such as molecular weight,
topological polar surface area, lipophilicity, and hydrogen bond donors/acceptors.</p>
      <p>In addition to the rule of 5 evaluation, it is important to identify
and address structural alerts in the proposed drug molecule. Structural
alerts are functional groups or substructures that have been associated
with toxicity or poor bioavailability in previous drug development
studies. By identifying and removing structural alerts in the design
phase, drug discovery teams can increase the chances of success in
clinical trials and decrease the risk of late-stage attritions due
to safety or efficacy concerns. Here, we provide BMS Rule,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Chelator Rule,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> PAINS
Rule,<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Genotoxic Carcinogenicity Rule,<sup><xref ref-type="bibr" rid="ref29">29</xref>−<xref ref-type="bibr" rid="ref32">32</xref></sup> NTD Rule,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> and SureChEMBL Rule<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> structural alerts.</p>
    </sec>
    <sec id="sec2.4.2">
      <label>5.2</label>
      <title>ADMET
Prediction</title>
      <p>ADMET prediction
is a crucial aspect of drug discovery and development. ADMET prediction
plays a vital role in predicting the safety and efficacy of a drug
before it is tested in clinical trials, which helps to reduce the
risk of drug failure and ensures patient safety. In the platform, <italic>Absorption</italic> is assessed by Caco2, Human Intestinal Absorption
(HIA), and P-glycoprotein (P-gp) Inhibitor. <italic>Bioavailability</italic> is assessed by Hydration Free Energy (HFE), Distribution, Blood-Brain
Barrier (BBB) Penetration, Plasma Protein Binding Ratio (PPBR), and
Volume of Distribution (VDSS). <italic>Metabolism</italic> is assessed
by CYP2D6 Inhibitor, CYP3A4 Inhibitor, CYP2C9 Inhibitor, CYP2D6 Substrate,
CYP3A4 Substrate, CYP2C9 Substrate, CYP2C19 Inhibitor, and CYP1A2
Inhibitor. Excretion is assessed by Half Life (hour) and Clearance
(mL/min/g). <italic>Toxicity</italic> is assessed by hERG, Drug-induced
Liver Injury (DILI), Aryl hydrocarbon Receptor (NR-AhR), Carcinogencity,
Median Lethal Dose (LD<sub>50</sub>), Respiratory toxicity, and Eye
Corrosion. The databases and methods used in ADMET prediction are
listed in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>.</p>
    </sec>
    <sec id="sec2.4.3">
      <label>5.3</label>
      <title>Binding Mode Assessment</title>
      <p>To rapidly
analyze the interaction characteristics between molecules and ligands,
the interactions present in different ways: (1) a 3D viewer of protein
and ligand (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a) [A 3D viewer of protein ligand allows researchers to visualize
and explore the spatial arrangement between a protein and a ligand
molecule. It provides valuable insights for drug design and optimization.];
(2) binding mode analysis (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b), i.e., the interactions between ligand and receptor
represented by different colors depend on the type of force; and (3)
binding site analysis (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>c), i.e., statistical analysis of binding sites for the possible
conformations of ligands. The vertical coordinate is the number of
ligand conformations predicted by AI, and the horizontal coordinate
is the amino acid site; different color statistics correspond to different
types of binding forces, and the statistics represent the number of
conformations where the current ligand has a binding force with that
amino acid site. More analysis tools such as toxic substructure hints,
generation of proprietary molecular reports, etc. will be added to
this module in the future.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>(a) 3D viewer of the protein and ligand, (b)
binding mode of the
ligand-protein, and (c) the analysis of interaction of the residue.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec2.5">
    <label>6</label>
    <title>Others</title>
    <sec id="sec2.5.1">
      <label>6.1</label>
      <title>User
Interface</title>
      <p>Recognizing that not
all users possess expertise in drug discovery software, the MolProphet
platform was carefully developed to ensure user-friendliness, minimizing
any potential hurdles. Each functional module within the system has
been streamlined to require just a few simple clicks, and every step
is accompanied by helpful hints to guide the users. This intuitive
design approach empowers ordinary users to swiftly navigate the platform
and effectively carry out projects, even without prior experience.</p>
      <p>Moreover, the MolProphet platform has preset multitype input data
methods for all modules (such as defining target pockets, submitting
reference molecules, etc.) to meet different usage scenarios. For
instance, when defining target pockets, users have the option to upload
local files for instant processing or search for standard PDB files
using PDB IDs sourced from the official PDB Web site (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</uri>). Similarly,
when setting reference molecules, users can choose from multiple options,
including direct molecular structure drawing, uploading local files,
inputting SMILES, or reading collection records. These flexible input
methods empower users to conveniently tailor their interactions with
the platform based on their specific needs.</p>
      <p>For result management,
the MolProphet platform provides task objectives
and conclusion record functions for each task, which provides convenience
for later review and also facilitates communication among users. Users
can also freely collect, download, and delete the results to meet
the needs of different scenarios. For each specific result molecule,
depending on the task, a corresponding result analysis interface is
provided, which can be viewed by clicking on the corresponding molecule
tab.</p>
      <p>In the future, the MolProphet platform will add more content
related
to results and records, including but not limited to automatically
generated task reports, molecular reports, experimental record management,
etc.</p>
    </sec>
    <sec id="sec2.5.2">
      <label>6.2</label>
      <title>Management System</title>
      <p>For project management,
the MolProphet platform establishes a set of project-based data management
solutions to solve users’ data management problems. Users can
create multiple projects with data isolated from each other. Each
project can invite different users to collaborate and share information
with the project. The platform also establishes an independent three-level
management system (PI, administrator, and general members) for each
project, which is convenient for users to manage their own research
teams.</p>
      <p>In terms of task management, users can check the progress
of tasks at any time while they are in progress, and they are also
allowed to cancel tasks that are in queue or in progress and to retry
at any time if there is an abnormality in the task (in some scenarios,
retrying can solve the abnormality). However, to avoid management
confusion, the platform restricts users from managing only the tasks
they have created.</p>
      <p>On the other hand, the platform separately
establishes a hybrid
cloud system for teams or companies with higher requirements of privacy
and confidentiality (e.g., pharmaceutical companies and research teams
with corresponding needs, etc.). It enables the instant distribution
of the latest models from the public cloud and ensures the security
of private cloud data.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>7</label>
    <title>Applications</title>
    <p>The
development of MolProphet
started in 2017, and since then,
the platform has been used in more than 20 hit discovery and lead
optimization projects with impressive results. The SaaS platform has
more than 400 users and has served in more than 600 projects until
today (December 10, 2023). The platform has been successful in identifying
compounds at the micromolar level, which have been further optimized
to achieve nanomolar levels. More details of application cases are
provided in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">Supporting Information</ext-link>.</p>
  </sec>
  <sec id="sec4">
    <label>8</label>
    <title>Conclusion</title>
    <p>MolProphet is a one-stop,
general purpose, and AI-based platform
for the early stages of small molecule drug discovery. It aims to
provide AI-based drug discovery tools to each normal researcher in
drug discovery. With MolProphet, users can access the platform from
anywhere, eliminating the need for a complex hardware or software
setup. Even without extensive knowledge in computational aid drug
discovery and AI, researchers in drug discovery can easily harness
the power of AIDD (AI-assisted drug discovery) to accelerate their
work.</p>
    <p>According to the practice in the industry, the platform
offers
a comprehensive suite of AI-based drug discovery tools for the early
stages of drug development. These include virtual screening, molecular
generation, and optimization functions. Our patented molecule generation
approach allows for direct generation of molecules from building blocks,
resulting in compounds with enhanced drug-likeness but easier and
cheaper to synthesize. The compound results from the virtual screening
are purchasable. In the optimization modules, the compounds can be
optimized by scaffold hopping, fragment, and R-group, which are valuable
for lead optimization.</p>
    <p>In summary, MolProphet is a valuable
online AIDD tool that empowers
researchers to accelerate their work in the early stages of small
molecule drug development.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes-2">
    <title>Data Availability Statement</title>
    <p>The software
is publicly available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.molprophet.com/">https://www.molprophet.com/</uri>. Many modules, including virtual screening, are freely accessible
to all users. Trial software licenses can be provided to interested
readers. Data for training the models is constructed from publicly
available sources such as ChEMBL (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/">https://www.ebi.ac.uk/chembl/</uri>).</p>
  </notes>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting
Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.3c01979?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.3c01979</ext-link>.<list id="silist" list-type="simple"><list-item><p>1. Test application case
on MolProphet, 2. Software
technology framework of MolProphet, 3. Methods and the theoretical
background of modules, 4. Stability of AI molecule generation, 5.
Databases and methods used in ADMET prediction, 6. Fine-tune modules
with wet-lab experimental data, 7. The original images of <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01979/suppl_file/ci3c01979_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01979_si_001.pdf">
        <caption>
          <p>ci3c01979_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e747-autogenerated">
    <p>The authors declare no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work is
supported by the Fundamental
Research Funds for
the Central Universities, grant No. 2022ZFJH003, the Ministry of Science
and Technology of the People’s Republic of China (No. G2022016010L),
the Scientific Research Fund of Zhejiang Provincial Education Department
(No. Y202352312), the Zhejiang Health Information Association Research
Program (No. 2023XHSZ-Z05), and the Natural Science Foundation of
Zhejiang Province (No. LD22H300004).</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Paul</surname><given-names>D.</given-names></name>; <name><surname>Sanap</surname><given-names>G.</given-names></name>; <name><surname>Shenoy</surname><given-names>S.</given-names></name>; <name><surname>Kalyane</surname><given-names>D.</given-names></name>; <name><surname>Kalia</surname><given-names>K.</given-names></name>; <name><surname>Tekade</surname><given-names>R. K.</given-names></name><article-title>Artificial intelligence
in drug discovery and development</article-title>. <source>DRUG DISCOV
TODAY</source><year>2021</year>, <volume>26</volume>, <fpage>80</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.10.010</pub-id>.<pub-id pub-id-type="pmid">33099022</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="book" id="cit2"><person-group person-group-type="allauthors"><name><surname>Ramsundar</surname><given-names>B.</given-names></name>; <name><surname>Eastman</surname><given-names>P.</given-names></name>; <name><surname>Walters</surname><given-names>P.</given-names></name>; <name><surname>Pande</surname><given-names>V.</given-names></name>; <name><surname>Leswing</surname><given-names>K.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name></person-group><source>Deep Learning for the Life Sciences</source>; <publisher-name>O’Reilly Media</publisher-name>: <year>2019</year>.</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Gentile</surname><given-names>F.</given-names></name>; <name><surname>Agrawal</surname><given-names>V.</given-names></name>; <name><surname>Hsing</surname><given-names>M.</given-names></name>; <name><surname>Ton</surname><given-names>A.</given-names></name>; <name><surname>Ban</surname><given-names>F.</given-names></name>; <name><surname>Norinder</surname><given-names>U.</given-names></name>; <name><surname>Gleave</surname><given-names>M. E.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name><article-title>Deep Docking:
A Deep Learning Platform for Augmentation of Structure Based Drug
Discovery</article-title>. <source>ACS CENTRAL SCI</source><year>2020</year>, <volume>6</volume>, <fpage>939</fpage>–<lpage>949</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.0c00229</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Aggarwal</surname><given-names>R.</given-names></name>; <name><surname>Gupta</surname><given-names>A.</given-names></name>; <name><surname>Chelur</surname><given-names>V.</given-names></name>; <name><surname>Jawahar</surname><given-names>C. V.</given-names></name>; <name><surname>Priyakumar</surname><given-names>U. D.</given-names></name><article-title>DeepPocket:
Ligand Binding Site Detection and Segmentation using 3D Convolutional
Neural Networks</article-title>. <source>J. CHEM INF MODEL</source><year>2022</year>, <volume>62</volume>, <fpage>5069</fpage>–<lpage>5079</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00799</pub-id>.<pub-id pub-id-type="pmid">34374539</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Jumper</surname><given-names>J.</given-names></name>; <name><surname>Evans</surname><given-names>R.</given-names></name>; <name><surname>Pritzel</surname><given-names>A.</given-names></name>; <name><surname>Green</surname><given-names>T.</given-names></name>; <name><surname>Figurnov</surname><given-names>M.</given-names></name>; <name><surname>Ronneberger</surname><given-names>O.</given-names></name>; <name><surname>Tunyasuvunakool</surname><given-names>K.</given-names></name>; <name><surname>Bates</surname><given-names>R.</given-names></name>; <name><surname>Žídek</surname><given-names>A.</given-names></name>; <name><surname>Potapenko</surname><given-names>A.</given-names></name>; <name><surname>Bridgland</surname><given-names>A.</given-names></name>; <name><surname>Meyer</surname><given-names>C.</given-names></name>; <name><surname>Kohl</surname><given-names>S. A. A.</given-names></name>; <name><surname>Ballard</surname><given-names>A. J.</given-names></name>; <name><surname>Cowie</surname><given-names>A.</given-names></name>; <name><surname>Romera-Paredes</surname><given-names>B.</given-names></name>; <name><surname>Nikolov</surname><given-names>S.</given-names></name>; <name><surname>Jain</surname><given-names>R.</given-names></name>; <name><surname>Adler</surname><given-names>J.</given-names></name>; <name><surname>Back</surname><given-names>T.</given-names></name>; <name><surname>Petersen</surname><given-names>S.</given-names></name>; <name><surname>Reiman</surname><given-names>D.</given-names></name>; <name><surname>Clancy</surname><given-names>E.</given-names></name>; <name><surname>Zielinski</surname><given-names>M.</given-names></name>; <name><surname>Steinegger</surname><given-names>M.</given-names></name>; <name><surname>Pacholska</surname><given-names>M.</given-names></name>; <name><surname>Berghammer</surname><given-names>T.</given-names></name>; <name><surname>Bodenstein</surname><given-names>S.</given-names></name>; <name><surname>Silver</surname><given-names>D.</given-names></name>; <name><surname>Vinyals</surname><given-names>O.</given-names></name>; <name><surname>Senior</surname><given-names>A. W.</given-names></name>; <name><surname>Kavukcuoglu</surname><given-names>K.</given-names></name>; <name><surname>Kohli</surname><given-names>P.</given-names></name>; <name><surname>Hassabis</surname><given-names>D.</given-names></name><article-title>Highly accurate protein
structure prediction with AlphaFold</article-title>. <source>NATURE</source><year>2021</year>, <volume>596</volume>, <fpage>583</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>.<pub-id pub-id-type="pmid">34265844</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Thiessen</surname><given-names>P. A.</given-names></name>; <name><surname>Bolton</surname><given-names>E. E.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Fu</surname><given-names>G.</given-names></name>; <name><surname>Gindulyte</surname><given-names>A.</given-names></name>; <name><surname>Han</surname><given-names>L.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>S.</given-names></name>; <name><surname>Shoemaker</surname><given-names>B. A.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Yu</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Bryant</surname><given-names>S. H.</given-names></name><article-title>PubChem
Substance and Compound databases</article-title>. <source>NUCLEIC ACIDS
RES</source><year>2016</year>, <volume>44</volume>, <fpage>D1202</fpage>–<lpage>D1213</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id>.<pub-id pub-id-type="pmid">26400175</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Bellis</surname><given-names>L. J.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>Davies</surname><given-names>M.</given-names></name>; <name><surname>Krüger</surname><given-names>F. A.</given-names></name>; <name><surname>Light</surname><given-names>Y.</given-names></name>; <name><surname>Mak</surname><given-names>L.</given-names></name>; <name><surname>McGlinchey</surname><given-names>S.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; <name><surname>Papadatos</surname><given-names>G.</given-names></name>; <name><surname>Santos</surname><given-names>R.</given-names></name>; <name><surname>Overington</surname><given-names>J. P.</given-names></name><article-title>The ChEMBL
bioactivity database:
an update</article-title>. <source>NUCLEIC ACIDS RES</source><year>2014</year>, <volume>42</volume>, <fpage>D1083</fpage>–<lpage>D1090</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1031</pub-id>.<pub-id pub-id-type="pmid">24214965</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Pence</surname><given-names>H. E.</given-names></name>; <name><surname>Williams</surname><given-names>A.</given-names></name><article-title>ChemSpider: An Online
Chemical Information Resource</article-title>. <source>J. CHEM EDUC</source><year>2010</year>, <volume>87</volume>, <fpage>1123</fpage>–<lpage>1124</lpage>. <pub-id pub-id-type="doi">10.1021/ed100697w</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Tang</surname><given-names>K. G.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Dandarchuluun</surname><given-names>C.</given-names></name>; <name><surname>Wong</surname><given-names>B. R.</given-names></name>; <name><surname>Khurelbaatar</surname><given-names>M.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Mayfield</surname><given-names>J.</given-names></name>; <name><surname>Sayle</surname><given-names>R. A.</given-names></name><article-title>ZINC20-A Free Ultralarge-Scale
Chemical Database for
Ligand Discovery</article-title>. <source>J. CHEM INF MODEL</source><year>2020</year>, <volume>60</volume>, <fpage>6065</fpage>–<lpage>6073</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00675</pub-id>.<pub-id pub-id-type="pmid">33118813</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Wishart</surname><given-names>D. S.</given-names></name>; <name><surname>Feunang</surname><given-names>Y. D.</given-names></name>; <name><surname>Guo</surname><given-names>A. C.</given-names></name>; <name><surname>Lo</surname><given-names>E. J.</given-names></name>; <name><surname>Marcu</surname><given-names>A.</given-names></name>; <name><surname>Grant</surname><given-names>J. R.</given-names></name>; <name><surname>Sajed</surname><given-names>T.</given-names></name>; <name><surname>Johnson</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Sayeeda</surname><given-names>Z.</given-names></name>; <name><surname>Assempour</surname><given-names>N.</given-names></name>; <name><surname>Iynkkaran</surname><given-names>I.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Maciejewski</surname><given-names>A.</given-names></name>; <name><surname>Gale</surname><given-names>N.</given-names></name>; <name><surname>Wilson</surname><given-names>A.</given-names></name>; <name><surname>Chin</surname><given-names>L.</given-names></name>; <name><surname>Cummings</surname><given-names>R.</given-names></name>; <name><surname>Le</surname><given-names>D.</given-names></name>; <name><surname>Pon</surname><given-names>A.</given-names></name>; <name><surname>Knox</surname><given-names>C.</given-names></name>; <name><surname>Wilson</surname><given-names>M.</given-names></name><article-title>DrugBank 5.0: a major
update to the DrugBank database
for 2018</article-title>. <source>NUCLEIC ACIDS RES</source><year>2018</year>, <volume>46</volume>, <fpage>D1074</fpage>–<lpage>D1082</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="book" id="cit11"><person-group person-group-type="allauthors"><name><surname>Tang</surname><given-names>B.</given-names></name>; <name><surname>Ewalt</surname><given-names>J.</given-names></name>; <name><surname>Ng</surname><given-names>H.</given-names></name></person-group><article-title>Generative AI
Models for Drug Discovery</article-title>. In <source>Biophysical
and Computational Tools in Drug Discovery</source>; <person-group person-group-type="editor"><name><surname>Saxena</surname><given-names>A. K.</given-names></name></person-group>, Ed.; <publisher-name>Springer
International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2021</year>; pp <fpage>221</fpage>–<lpage>243</lpage>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D.</given-names></name>; <name><surname>Bezrukov</surname><given-names>D.</given-names></name>; <name><surname>Zagribelnyy</surname><given-names>B.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V.</given-names></name>; <name><surname>Kamya</surname><given-names>P.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Ren</surname><given-names>F.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>Chemistry42:
An AI-Driven Platform for Molecular Design
and Optimization</article-title>. <source>J. CHEM INF MODEL</source><year>2023</year>, <volume>63</volume>, <fpage>695</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.2c01191</pub-id>.<pub-id pub-id-type="pmid">36728505</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Veselov</surname><given-names>M. S.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V. A.</given-names></name>; <name><surname>Aladinskaya</surname><given-names>A. V.</given-names></name>; <name><surname>Terentiev</surname><given-names>V. A.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D. A.</given-names></name>; <name><surname>Kuznetsov</surname><given-names>M. D.</given-names></name>; <name><surname>Asadulaev</surname><given-names>A.</given-names></name>; <name><surname>Volkov</surname><given-names>Y.</given-names></name>; <name><surname>Zholus</surname><given-names>A.</given-names></name>; <name><surname>Shayakhmetov</surname><given-names>R. R.</given-names></name>; <name><surname>Zhebrak</surname><given-names>A.</given-names></name>; <name><surname>Minaeva</surname><given-names>L. I.</given-names></name>; <name><surname>Zagribelnyy</surname><given-names>B. A.</given-names></name>; <name><surname>Lee</surname><given-names>L. H.</given-names></name>; <name><surname>Soll</surname><given-names>R.</given-names></name>; <name><surname>Madge</surname><given-names>D.</given-names></name>; <name><surname>Xing</surname><given-names>L.</given-names></name>; <name><surname>Guo</surname><given-names>T.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name><article-title>Deep learning enables rapid identification of potent
DDR1 kinase inhibitors</article-title>. <source>NAT BIOTECHNOL</source><year>2019</year>, <volume>37</volume>, <fpage>1038</fpage>–<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-019-0224-x</pub-id>.<pub-id pub-id-type="pmid">31477924</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="undeclared" id="cit14"><person-group person-group-type="allauthors"><name><surname>Lowe</surname><given-names>D.</given-names></name></person-group><source>Chemical reactions from
US patents (1976-Sep2016)</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://figshare.com/articles/dataset/Chemical_reactions_from_US_patents_1976-Sep2016_/5104873/1">https://figshare.com/articles/dataset/Chemical_reactions_from_US_patents_1976-Sep2016_/5104873/1</uri> (accessed Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Sadybekov</surname><given-names>A. A.</given-names></name>; <name><surname>Sadybekov</surname><given-names>A. V.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Iliopoulos-Tsoutsouvas</surname><given-names>C.</given-names></name>; <name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Pickett</surname><given-names>J.</given-names></name>; <name><surname>Houser</surname><given-names>B.</given-names></name>; <name><surname>Patel</surname><given-names>N.</given-names></name>; <name><surname>Tran</surname><given-names>N. K.</given-names></name>; <name><surname>Tong</surname><given-names>F.</given-names></name>; <name><surname>Zvonok</surname><given-names>N.</given-names></name>; <name><surname>Jain</surname><given-names>M. K.</given-names></name>; <name><surname>Savych</surname><given-names>O.</given-names></name>; <name><surname>Radchenko</surname><given-names>D. S.</given-names></name>; <name><surname>Nikas</surname><given-names>S. P.</given-names></name>; <name><surname>Petasis</surname><given-names>N. A.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Makriyannis</surname><given-names>A.</given-names></name>; <name><surname>Katritch</surname><given-names>V.</given-names></name><article-title>Synthon-based ligand discovery in
virtual libraries
of over 11 billion compounds</article-title>. <source>NATURE</source><year>2022</year>, <volume>601</volume>, <fpage>452</fpage>–<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-04220-9</pub-id>.<pub-id pub-id-type="pmid">34912117</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bellis</surname><given-names>L. J.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>Davies</surname><given-names>M.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Light</surname><given-names>Y.</given-names></name>; <name><surname>McGlinchey</surname><given-names>S.</given-names></name>; <name><surname>Michalovich</surname><given-names>D.</given-names></name>; <name><surname>Al-Lazikani</surname><given-names>B.</given-names></name>; <name><surname>Overington</surname><given-names>J. P.</given-names></name><article-title>ChEMBL:
a large-scale bioactivity database for drug discovery</article-title>. <source>NUCLEIC ACIDS RES</source><year>2012</year>, <volume>40</volume>, <fpage>D1100</fpage>–<lpage>D1107</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkr777</pub-id>.<pub-id pub-id-type="pmid">21948594</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Zdrazil</surname><given-names>B.</given-names></name>; <name><surname>Felix</surname><given-names>E.</given-names></name>; <name><surname>Hunter</surname><given-names>F.</given-names></name>; <name><surname>Manners</surname><given-names>E. J.</given-names></name>; <name><surname>Blackshaw</surname><given-names>J.</given-names></name>; <name><surname>Corbett</surname><given-names>S.</given-names></name>; <name><surname>de Veij</surname><given-names>M.</given-names></name>; <name><surname>Ioannidis</surname><given-names>H.</given-names></name>; <name><surname>Lopez</surname><given-names>D. M.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Magarinos</surname><given-names>M. P.</given-names></name>; <name><surname>Bosc</surname><given-names>N.</given-names></name>; <name><surname>Arcila</surname><given-names>R.</given-names></name>; <name><surname>Kiziloren</surname><given-names>T.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Adasme</surname><given-names>M. F.</given-names></name>; <name><surname>Monecke</surname><given-names>P.</given-names></name>; <name><surname>Landrum</surname><given-names>G. A.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name><article-title>The ChEMBL Database in 2023: a drug
discovery platform spanning multiple bioactivity data types and time
periods</article-title>. <source>NUCLEIC ACIDS RES</source><year>2024</year>, <volume>52</volume>, <fpage>D1180</fpage>–<lpage>D1192</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkad1004</pub-id>.<pub-id pub-id-type="pmid">37933841</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="weblink" id="cit18"><person-group><collab>ChemBridge</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chembridge.com/">https://chembridge.com/</uri> (accessed
Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="weblink" id="cit19"><person-group><collab>ChemDiv</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chemdiv.com/catalog/screening-libraries/">https://www.chemdiv.com/catalog/screening-libraries/</uri> (accessed Feb. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="weblink" id="cit20"><person-group><collab>Chemspace</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chem-space.com/">https://chem-space.com/</uri> (accessed
Jun. 16, 2023).</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="weblink" id="cit21"><person-group><collab>Enamine</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://enamine.net/compound-collections/screening-collection">https://enamine.net/compound-collections/screening-collection</uri> (accessed Mar. 26, 2024).</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="weblink" id="cit22"><person-group><collab>Enamine Covalent
Compounds</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://enamine.net/compound-collections/covalent-compounds">https://enamine.net/compound-collections/covalent-compounds</uri> (accessed Jun. 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="weblink" id="cit23"><person-group><collab>IBS Interbioscreen</collab></person-group>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ibscreen.com/bases">https://www.ibscreen.com/bases</uri> (accessed Jun. 18, 2023).</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Tang</surname><given-names>K. G.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Dandarchuluun</surname><given-names>C.</given-names></name>; <name><surname>Wong</surname><given-names>B. R.</given-names></name>; <name><surname>Khurelbaatar</surname><given-names>M.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Mayfield</surname><given-names>J.</given-names></name>; <name><surname>Sayle</surname><given-names>R. A.</given-names></name><article-title>ZINC20—A
Free Ultralarge-Scale Chemical Database
for Ligand Discovery</article-title>. <source>J. CHEM INF MODEL</source><year>2020</year>, <volume>60</volume>, <fpage>6065</fpage>–<lpage>6073</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00675</pub-id>.<pub-id pub-id-type="pmid">33118813</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Shultz</surname><given-names>M. D.</given-names></name><article-title>Two Decades
under the Influence of the Rule of Five and the Changing Properties
of Approved Oral Drugs</article-title>. <source>J. MED CHEM</source><year>2019</year>, <volume>62</volume>, <fpage>1701</fpage>–<lpage>1714</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00686</pub-id>.<pub-id pub-id-type="pmid">30212196</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Huth</surname><given-names>J. R.</given-names></name>; <name><surname>Mendoza</surname><given-names>R.</given-names></name>; <name><surname>Olejniczak</surname><given-names>E. T.</given-names></name>; <name><surname>Johnson</surname><given-names>R. W.</given-names></name>; <name><surname>Cothron</surname><given-names>D. A.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Lerner</surname><given-names>C. G.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Hajduk</surname><given-names>P. J.</given-names></name><article-title>ALARM NMR: a rapid
and robust experimental method to detect reactive false positives
in biochemical screens</article-title>. <source>J. AM CHEM SOC</source><year>2005</year>, <volume>127</volume>, <fpage>217</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1021/ja0455547</pub-id>.<pub-id pub-id-type="pmid">15631471</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Agrawal</surname><given-names>A.</given-names></name>; <name><surname>Johnson</surname><given-names>S. L.</given-names></name>; <name><surname>Jacobsen</surname><given-names>J. A.</given-names></name>; <name><surname>Miller</surname><given-names>M. T.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Pellecchia</surname><given-names>M.</given-names></name>; <name><surname>Cohen</surname><given-names>S. M.</given-names></name><article-title>Chelator Fragment Libraries for Targeting
Metalloproteinases</article-title>. <source>CHEMMEDCHEM</source><year>2010</year>, <volume>5</volume>, <fpage>195</fpage>–<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200900516</pub-id>.<pub-id pub-id-type="pmid">20058293</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Baell</surname><given-names>J. B.</given-names></name>; <name><surname>Holloway</surname><given-names>G. A.</given-names></name><article-title>New Substructure
Filters for Removal of Pan Assay Interference
Compounds (PAINS) from Screening Libraries and for Their Exclusion
in Bioassays</article-title>. <source>J. MED CHEM</source><year>2010</year>, <volume>53</volume>, <fpage>2719</fpage>–<lpage>2740</lpage>. <pub-id pub-id-type="doi">10.1021/jm901137j</pub-id>.<pub-id pub-id-type="pmid">20131845</pub-id></mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Benigni</surname><given-names>R.</given-names></name>; <name><surname>Bossa</surname><given-names>C.</given-names></name><article-title>Structure alerts for
carcinogenicity, and the Salmonella assay system:
a novel insight through the chemical relational databases technology</article-title>. <source>MUTAT RES-FUND MOL M</source><year>2008</year>, <volume>659</volume>, <fpage>248</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrrev.2008.05.003</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Ashby</surname><given-names>J.</given-names></name>; <name><surname>Tennant</surname><given-names>R. W.</given-names></name><article-title>Chemical structure, Salmonella mutagenicity
and extent
of carcinogenicity as indicators of genotoxic carcinogenesis among
222 chemicals tested in rodents by the U.S. NCI/NTP</article-title>. <source>Mutation Research/Genetic Toxicology</source><year>1988</year>, <volume>204</volume>, <fpage>17</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/0165-1218(88)90114-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Kazius</surname><given-names>J.</given-names></name>; <name><surname>McGuire</surname><given-names>R.</given-names></name>; <name><surname>Bursi</surname><given-names>R.</given-names></name><article-title>Derivation
and Validation of Toxicophores
for Mutagenicity Prediction</article-title>. <source>J. MED CHEM</source><year>2005</year>, <volume>48</volume>, <fpage>312</fpage>–<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1021/jm040835a</pub-id>.<pub-id pub-id-type="pmid">15634026</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Bailey</surname><given-names>A. B.</given-names></name>; <name><surname>Chanderbhan</surname><given-names>R.</given-names></name>; <name><surname>Collazo-Braier</surname><given-names>N.</given-names></name>; <name><surname>Cheeseman</surname><given-names>M. A.</given-names></name>; <name><surname>Twaroski</surname><given-names>M. L.</given-names></name><article-title>The use of structure–activity
relationship analysis
in the food contact notification program</article-title>. <source>REGUL
TOXICOL PHARM</source><year>2005</year>, <volume>42</volume>, <fpage>225</fpage>–<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2005.04.006</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Brenk</surname><given-names>R.</given-names></name>; <name><surname>Schipani</surname><given-names>A.</given-names></name>; <name><surname>James</surname><given-names>D.</given-names></name>; <name><surname>Krasowski</surname><given-names>A.</given-names></name>; <name><surname>Gilbert</surname><given-names>I. H.</given-names></name>; <name><surname>Frearson</surname><given-names>J.</given-names></name>; <name><surname>Wyatt</surname><given-names>P. G.</given-names></name><article-title>Lessons learnt from
assembling screening libraries for drug discovery for neglected diseases</article-title>. <source>CHEMMEDCHEM</source><year>2008</year>, <volume>3</volume>, <fpage>435</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200700139</pub-id>.<pub-id pub-id-type="pmid">18064617</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Sushko</surname><given-names>I.</given-names></name>; <name><surname>Salmina</surname><given-names>E.</given-names></name>; <name><surname>Potemkin</surname><given-names>V. A.</given-names></name>; <name><surname>Poda</surname><given-names>G.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name><article-title>ToxAlerts:
A Web Server of Structural Alerts for Toxic Chemicals and Compounds
with Potential Adverse Reactions</article-title>. <source>J. CHEM INF
MODEL</source><year>2012</year>, <volume>52</volume>, <fpage>2310</fpage>–<lpage>2316</lpage>. <pub-id pub-id-type="doi">10.1021/ci300245q</pub-id>.<pub-id pub-id-type="pmid">22876798</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
